WO2003020763A2 - Soluble t cell receptor - Google Patents
Soluble t cell receptor Download PDFInfo
- Publication number
- WO2003020763A2 WO2003020763A2 PCT/GB2002/003986 GB0203986W WO03020763A2 WO 2003020763 A2 WO2003020763 A2 WO 2003020763A2 GB 0203986 W GB0203986 W GB 0203986W WO 03020763 A2 WO03020763 A2 WO 03020763A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tcr
- chain
- stcr
- soluble
- exon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the MHC class I and class II ligands are also immunoglobulm superfamily proteins but are specialised for antigen presentation, with a polymorphic peptide binding site which enables them to present a diverse array of short peptide fragments at the APC cell surface.
- Soluble TCRs are useful, not only for the purpose of investigating specific TCR- pMHC interactions, but also potentially as a diagnostic tool to detect infection, or to detect autoimmune disease markers. Soluble TCRs also have applications in staining, for example to stain cells for the presence of a particular peptide antigen presented in the context of the MHC. Similarly, soluble TCRs can be used to deliver a therapeutic agent, for example a cytotoxic compound or an immunostimulating compound, to cells presenting a particular antigen. Soluble TCRs may also be used to inhibit T cells, for example, those reacting to an auto-immune peptide antigen.
- a therapeutic agent for example a cytotoxic compound or an immunostimulating compound
- TCRs can be recognised by TCR- specific antibodies, none were shown to recognise its native ligand at anything other than relatively high concentrations and/or were not stable.
- a soluble TCR which is correctly folded so that it is capable of recognising its native ligand, is stable over a period of time, and can be produced in reasonable quantities.
- This TCR comprises a TCR or ⁇ chain extracellular domain dimerised to a TCR ⁇ or ⁇ chain extracellular domain respectively, by means of a pair of C-terminal dimerisation peptides, such as leucine zippers.
- This strategy of producing TCRs is generally applicable to all TCRs.
- the present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR ⁇ chain, except the transmembrane domain thereof, and (ii) all or part of a TCR ⁇ chain, except the transmembrane domain thereof, wherein (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.
- sTCR soluble T cell receptor
- the invention provides a soluble ⁇ -form T cell receptor (sTCR), wherein a covalent disulphide bond links a residue of the immunoglobulm region of the constant domain of the ⁇ chain to a residue of the immunoglobulm region of the constant domain of the ⁇ chain.
- sTCR soluble ⁇ -form T cell receptor
- the sTCRs of the present invention have the advantage that they do not contain heterologous polypeptides which may be immunogenic, or which may result in the sTCR being cleared quickly from the body. Furthermore, TCRs of the present invention have a three-dimensional structure which is highly similar to the native TCRs from which they are derived and, due to this structural similarity, they are not likely to be immunogenic. sTCRs in accordance with the invention may be for recognising Class I MHC-peptide complexes or Class H MHC-peptide complexes.
- TCRs of the present invention are soluble.
- solubility is defined as the ability of the TCR to be purified as a mono disperse heterodimer in phosphate buffered saline (PBS) (KCL 2.7mM, KH 2 PO 4 1.5mM, NaCl 137mM and Na 2 PO4 8mM, pH 7.1-7.5. Life Technologies, Gibco BRL) at a concentration of lmg/ml and for >90% of said TCR to remain as a mono disperse heterodimer after incubation at 25 °C for 1 hour.
- PBS phosphate buffered saline
- the TCRs of the present invention are soluble. However, as explained in more detail below, the TCRs can be coupled to a moiety such that the resulting complex is insoluble, or they may be presented on the surface of an insoluble solid support.
- TCR amino acids used herein follows the EVIGT system described in The T Cell Receptor Factsbook, 2001, LeFranc & LeFranc, Academic Press.
- the ⁇ chain constant domain has the following notation: TRAC*01, where
- TR indicates T Cell Receptor gene
- A indicates ⁇ chain gene
- C indicates constant region
- *01 indicates allele 1.
- the ⁇ chain constant domain has the following notation: TRBC1*01. In this instance, there are two possible constant region genes "Cl” and "C2".
- the translated domain encoded by each allele can be made up from the genetic code of several exons; therefore these are also specified. Amino acids are numbered according to the exon of the particular domain in which they are present.
- the extracellular portion of native TCR consists of two polypeptides ( ⁇ or ⁇ ) each of which has a membrane-proximal constant domain, and a membrane-distal variable domain (see Figure 1). Each of the constant and variable domains includes an intra- chain disulphide bond.
- variable domains contain the highly polymorphic loops analogous to the complementarity determining regions (CDRs) of antibodies.
- CDR3 of the TCR interacts with the peptide presented by MHC, and CDRs 1 and 2 interact with the peptide and the MHC.
- the diversity of TCR sequences is generated via somatic rearrangement of linked variable (N), diversity D), joining (J), and constant genes.
- Functional ⁇ chain polypeptides are formed by rearranged N-J-C regions, whereas ⁇ chains consist of N-D-J-C regions.
- the extracellular constant domain has a membrane proximal region and an immunoglobulm region.
- the membrane proximal region consists of the amino acids between the transmembrane domain and the membrane proximal cysteine residue.
- the constant immunoglobulm domain consists of the remainder of the constant domain amino acid residues, extending from the membrane proximal cysteine to the beginning of the joining region, and is characterised by the presence of an immunoglobulin-type fold.
- the difference between these different ⁇ constant domains is in respect of amino acid residues 4, 5 and 37 of exon 1.
- TRBC1*01 has 4 ⁇ , 5K and 37 in exon 1 thereof, and
- TRBC2*01 has 4K, 5N and 37Y in exon 1 thereof.
- the extent of each of the TCR extracellular domains is somewhat variable.
- a preferred soluble TCR comprises the native ⁇ and ⁇ TCR chains truncated at the C-terminus such that the cysteine residues which form the native interchain disulphide bond are excluded, i.e. truncated at the residue 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 residues N-terminal to the cysteine residues. It is to be noted however that the native inter-chain disulphide bond may be present in
- TCRs of the present invention and that, in certain embodiments, only one of the TCR chains has the native cysteine residue which forms the native interchain disulphide bond. This cysteine can be used to attach moieties to the TCR.
- a methionine residue may be engineered onto the N-terminal starting point of the predicted mature protein sequence in order to enable initiation of translation.
- the TCR ⁇ chain contains a cysteine residue which is unpaired in the cellular or native TCR. It is preferred if this cysteine residue is removed or mutated to another residue to avoid incorrect intrachain or interchain pairing. Substitutions of this cysteine residue for another residue, for example serine or alanine, can have a significant positive effect on refolding efficiencies in vitro.
- residue 1 (according to the numbering used in Garboczi et al) is K and N respectively.
- the N-terminal methionine residue is not present in native A6 Tax TCR and, as mentioned above, is sometimes present when the respective chains are produced in bacterial expression systems.
- residues in human TCRs which can be mutated into cysteine residues to form a new interchain disulphide bond have been identified, those of skill in the art will be able to mutate any TCR in the same way to produce a soluble form of that TCR having a new interchain disulphide bond.
- the skilled person merely needs to look for the following motifs in the respective TCR chains to identify the residue to be mutated (the shaded residue is the residue for mutation to a cysteine).
- the TCR chains may not have a region which has 100% identity to the above motifs.
- those of skill in the art will be able to use the above motifs to identify the equivalent part of the TCR ⁇ or ⁇ chain and hence the residue to be mutated to cysteine. Alignment techniques may be used in this respect.
- ClustalW available on the European Bioinformatics Institute website (http://www.ebi.ac.uk/index.html) can be used to compare the motifs above to a particular TCR chain sequence in order to locate the relevant part of the TCR sequence for mutation.
- Murine equivalent of human ⁇ Chain Thr 48 ESGTFITDKIVLDMKAMDSK Murine equivalent of human ⁇ Chain Thr 45: KTMESGTFI
- Murine equivalent of human ⁇ Chain Tyr 10 YIQ ⁇ PEPANfjQLKDPRSQDS
- Murine equivalent of human ⁇ Chain Ser 77 KESNYSYCl
- Murine equivalent of human ⁇ Chain Asp 59 REVHSGVSTgPQAYKESNYS
- the constant domains of the A6 Tax sTCR described above, or indeed the constant domains of any of the mutant ⁇ TCRs having a new interchain disulphide bond described above, can be used as framework onto which heterologous variable domains can be fused. It is preferred if the fusion protein retains as much of the conformation of the heterologous variable domains as possible. Therefore, it is preferred that the heterologous variable domains are linked to the constant domains at any point between the introduced cysteine residues and the N terminus of the constant domain.
- the introduced cysteine residues on the ⁇ and ⁇ chains are preferably located at threonine 48 of exon 1 in TRAC*01 (threonine 158 of the ⁇ chain according to the numbering used in Garboczi et al) and serine 57 of exon 1 in both TRBC1*01 and TRBC2*01 (serine 172 of the ⁇ chain according to the numbering used in Garboczi et al) respectively.
- heterologous ⁇ and ⁇ chain variable domain attachment points are between residues 48 (159 according to the numbering used in Garboczi et al) or 58 (173 according to the numbering used in Garboczi et al) and the N terminus of the ⁇ or ⁇ constant domains respectively.
- the residues in the constant domains of the heterologous ⁇ and ⁇ chains corresponding to the attachment points in the A6 Tax TCR can be identified by sequence homology.
- the fusion protein is preferably constructed to include all of the heterologous sequence N-terminal to the attachment point.
- the sTCR of the present invention may be derivatised with, or fused to, a moiety at its C or N terminus.
- the C terminus is preferred as this is distal from the binding domain.
- one or both of the TCR chains have a cysteine residue at its C and/or N terminus to which such a moiety can be fused.
- the TCRs may be in the form of multimers, and/or may be present on or associated with a lipid bilayer, for example, a liposome.
- a multivalent TCR complex comprises a multimer of two or three or four or more T cell receptor molecules associated (e.g. covalently or otherwise linked) with one another, preferably via a linker molecule.
- Suitable linker molecules include, but are not limited to, multivalent attachment molecules such as avidin, streptavidin, neutravidin and extravidin, each of which has four binding sites for biotin.
- biotinylated TCR molecules can be formed into multimers of T cell receptors having a plurality of TCR binding sites.
- TCR molecules in the multimer will depend upon the quantity of TCR in relation to the quantity of linker molecule used to make the multimers, and also on the presence or absence of any other biotinylated molecules.
- Preferred multimers are dimeric, trimeric or tetrameric TCR complexes.
- Structures which are a good deal larger than TCR tetramers may be used in tracking or targeting cells expressing specific MHC-peptide complex.
- the structures are in the range lOnm to lO ⁇ m in diameter.
- Each structure may display multiple TCR molecules at a sufficient distance apart to enable two or more TCR molecules on the structure to bind simultaneously to two or more MHC-peptide complexes on a cell and thus increase the avidity of the multimeric binding moiety for the cell.
- Suitable structures for use in the invention include membrane structures such as liposomes and solid structures which are preferably particles such as beads, for example latex beads. Other structures which may be externally coated with T cell receptor molecules are also suitable.
- the structures are coated with T cell receptor multimers rather than with individual T cell receptor molecules.
- a label or another moiety, such as a toxic or therapeutic moiety, may be included in a multivalent TCR complex of the present invention.
- the label or other moiety may be included in a mixed molecule multimer.
- An example of such a multimeric molecule is a tetramer containing three TCR molecules and one peroxidase molecule. This could be achieved by mixing the TCR and the enzyme at a molar ratio of 3:1 to generate tetrameric complexes, and isolating the desired complex from any complexes not containing the correct ratio of molecules.
- These mixed molecules could contain any combination of molecules, provided that steric hindrance does not compromise or does not significantly compromise the desired function of the molecules.
- the positioning of the binding sites on the streptavidin molecule is suitable for mixed tetramers since steric hindrance is not likely to occur.
- biotinylating the TCR may be possible.
- chemical biotinylation may be used.
- biotmylation tags may be used, although certain amino acids in the biotin tag sequence are essential (Schatz, (1993). Biotechnology N Y 11(10): 1138-43).
- the mixture used for biotinylation may also be varied.
- the enzyme requires Mg-ATP and low ionic strength, although both of these conditions may be varied e.g. it may be possible to use a higher ionic strength and a longer reaction time. It may be possible to use a molecule other than avidin or streptavidin to form multimers of the TCR. Any molecule which binds biotin in a multivalent manner would be suitable.
- an entirely different linkage could be devised (such as poly-histidine tag to chelated nickel ion (Quiagen Product Guide 1999, Chapter 3 "Protein Expression, Purification, Detection and Assay” p. 35- 37).
- the tag is located towards the C-terminus of the protein so as to minimise the amount of steric hindrance in the interaction with peptide-MHC complexes.
- TCR-specific antibodies in particular monoclonal antibodies.
- anti-TCR antibodies such as ⁇ Fl and ⁇ Fl, which recognise the constant regions of the ⁇ and ⁇ chain, respectively.
- the invention also provides a method for delivering a therapeutic agent to a target cell, which method comprises contacting potential target cells with a TCR or multivalent TCR complex in accordance with the invention under conditions to allow attachment of the TCR or multivalent TCR complex to the target cell, said TCR or multivalent TCR complex being specific for the MHC-peptide complexes and having the therapeutic agent associated therewith.
- the soluble TCR or multivalent TCR complex can be used to deliver therapeutic agents to the location of cells presenting a particular antigen. This would be useful in many situations and, in particular, against tumours. A therapeutic agent could be delivered such that it would exercise its effect locally but not only on the cell it binds to.
- one particular strategy envisages anti-tumour molecules linked to T cell receptors or multivalent TCR complexes specific for tumour antigens.
- therapeutic agents could be employed for this use, for instance radioactive compounds, enzymes (perform for example) or chemotherapeutic agents (cis-platin for example).
- radioactive compounds for instance
- enzymes perform for example
- chemotherapeutic agents cis-platin for example.
- the toxin could be inside a liposome linked to streptavidin so that the compound is released slowly. This will prevent damaging effects during the transport in the body and ensure that the toxin has maximum effect after binding of the TCR to the relevant antigen presenting cells.
- Suitable therapeutic agents include:
- small molecule cytotoxic agents i.e. compounds with the ability to kill mammalian cells having a molecular weight of less than 700 daltons. Such compounds could also contain toxic metals capable of having a cytotoxic effect. Furthermore, it is to be understood that these small molecule cytotoxic agents also include pro-drugs, i.e. compounds that decay or are converted under physiological conditions to release cytotoxic agents.
- agents include cis-platin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodiumphotofrin ⁇ , temozolmide, topotecan, trimetreate glucuronate, auristatin E vincristine and doxorubicin; • peptide cytotoxins, i.e. proteins or fragments thereof with the ability to kill mammalian cells. Examples include ricin, diphtheria toxin, pseudomonas bacterial exotoxin A, DNAase and RNAase;
- radio-nuclides i.e. unstable isotopes of elements which decay with the concurrent emission of one or more of ⁇ or ⁇ particles, or ⁇ rays.
- radio-nuclides i.e. unstable isotopes of elements which decay with the concurrent emission of one or more of ⁇ or ⁇ particles, or ⁇ rays. Examples include iodine 131, rhenium 186, indium 111, yttrium 90, bismuth 210 and 213, actinium 225 and astatine 213;
- immuno-stimulants i.e. moieties which stimulate immune response.
- examples include cytokines such as IL-2, chemokines such as IL-8, platelet factor 4, melanoma growth stimulatory protein, etc, antibodies or fragments thereof, complement activators, xenogeneic protein domains, allogeneic protein domains, viral/bacterial protein domains and viral bacterial peptides.
- suitable MHC-peptide targets for the TCR according to the invention include, but are not limited to, viral epitopes such as HTLN-1 epitopes (e.g. the Tax peptide restricted by HLA-A2; HTLN-1 is associated with leukaemia), HIN epitopes, EBN epitopes, CMN epitopes; melanoma epitopes (e.g. MAGE-1 HLA-A1 restricted epitope) and other cancer-specific epitopes (e.g. the renal cell carcinoma associated antigen G250 restricted by HLA-A2); and epitopes associated with autoimmune disorders, such as rheumatoid arthritis.
- HTLN-1 epitopes e.g. the Tax peptide restricted by HLA-A2
- HTLN-1 is associated with leukaemia
- HIN epitopes e.g. the Tax peptide restricted by HLA-A2
- EBN epitopes e.g. the Tax peptide
- Viral diseases for which drugs exist would benefit from the drug being released or activated in the near vicinity of infected cells.
- the localisation in the vicinity of tumours or metastasis would enhance the effect of toxins or immunostimulants.
- immunosuppressive drugs could be released slowly, having more local effect over a longer time-span while minimally affecting the overall immuno-capacity of the subject.
- the effect of immunosuppressive drugs could be optimised in the same way.
- the vaccine antigen could be localised in the vicinity of antigen presenting cells, thus enhancing the efficacy of the antigen.
- the method can also be applied for imaging purposes.
- the soluble TCRs of the present invention may be used to modulate T cell activation by binding to specific pMHC and thereby inhibiting T cell activation.
- Autoimmune diseases involving T cell-mediated im ⁇ ammation and/or tissue damage would be amenable to this approach, for example type I diabetes.
- Knowledge of the specific peptide epitope presented by the relevant pMHC is required for this use.
- Medicaments in accordance with the invention will usually be supplied as. part of a sterile, pharmaceutical composition which will normally include a pharmaceutically acceptable carrier.
- This pharmaceutical composition may be in any suitable form, (depending upon the desired method of administering it to a patient). It may be provided in unit dosage form, will generally be provided in a sealed container and may be provided as part of a kit. Such a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.
- compositions adapted for oral a ⁇ riinistration may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions).
- Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
- Suitable excipients for use with soft gelatine capsules include for example vegetable oils, axes, fats, semi- solid, or liquid polyols etc.
- excipients which may be used include for example water, polyols and sugars.
- suspensions oils e.g. vegetable oils
- Pharmaceutical compositions adapted for transdermal adniinistration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
- the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6):318 (1986).
- Pharmaceutical compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
- compositions are preferably applied as a topical ointment or cream.
- the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
- the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
- compositions adapted for topical administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
- Pharmaceutical compositions adapted for topical in the mouth include lozenges, pastilles and mouth washes.
- compositions adapted for administration by inhalation include fine particle dusts or mists which maybe generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.
- Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
- Pharmaceutical compositions adapted for parenteral ad ⁇ iistration include aqueous and non-aqueous sterile injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the present invention provides a nucleic acid molecule comprising a sequence encoding a chain of the soluble TCR of the present invention, or a sequence complementary thereto.
- Such nucleic acid sequences may be obtained by isolating TCR-encoding nucleic acid from T-cell clones and making appropriate mutations (by insertion, deletion or substitution).
- Suitable techniques for such a screening method include the Surface Plasmon Resonance-based method described in WO 01/22084. Other well-known techniques that could form the basis of this screening method are Scintillation Proximity Analysis (SPA) and Amplified Luminescent Proximity Assay.
- Agents selected by screening methods of the invention can be used as drugs, or as the basis of a drug development programme, being modified or otherwise improved to have characteristics making them more suitable for administration as a medicament.
- Such medicaments can be used for the treatment of conditions which include an unwanted T cell response component.
- Such conditions include cancer (e.g. renal, ovarian, bowel, head & neck, testicular, lung, stomach, cervical, bladder, prostate or melanoma), autoimmune disease, graft rejection and graft versus host disease.
- Figures 2a and 2b show respectively the nucleic acid sequences of the ⁇ and ⁇ . chains of a soluble A6 TCR, mutated so as to introduce a cysteine codon. The shading indicates the introduced cysteine codon;
- Figure 3 a shows the A6 TCR ⁇ chain extracellular amino acid sequence, including the T 8 -» C mutation (underlined) used to produce the novel disulphide inter-chain bond
- Figure 3b shows the A6 TCR ⁇ chain extracellular amino acid sequence, including the S 57 -» C mutation (underlined) used to produce the novel disulphide inter-chain bond
- Figure 4 is a trace obtained after anion exchange chromatography of soluble A6 TCR, showing protein elution from a POROS 50HQ column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- FIG. 5 - A Reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 4, as indicated.
- B Non-reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 4, as indicated.
- Peak 1 clearly contains mainly non-disulphide linked ⁇ -chain
- peak 2 contains TCR heterodimer which is inter-chain disulphide linked
- the shoulder is due to E;coli contaminants, mixed in with the inter-chain disulphide linked sTCR, which are poorly visible on this reproduction;
- Figure 6 is a trace obtained from size-exclusion chromatography of pooled fractions from peak 1 in Figure 5.
- the protein elutes as a single major peak, corresponding to the heterodimer;
- Figure 7 is a BIAcore response curve of the specific binding of disulphide-linked A6 soluble TCR to HLA-A2-tax complex. Insert shows binding response compared to control for a single injection of disulphide-linked A6 soluble TCR;
- Figure 8a shows the A6 TCR ⁇ chain sequence including novel cysteine residue mutated to incorporate a BamHI restriction site. Shading indicates the mutations introduced to form the BamHI restriction site.
- Figures 8b and 8c show the DNA sequence of ⁇ and ⁇ chain of the JM22 TCR mutated to include additional cysteine residues to form a non-native disulphide bond;
- Figures 9a and 9b show respectively the JM22 TCR ⁇ and ⁇ chain extracellular amino acid sequences produced from the DNA sequences of Figures 8a and 8b;
- Figure 10 is a trace obtained after anion exchange chromatography of soluble disulphide-linked JM22 TCR showing protein elution from a POROS 50HQ column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- Figure 11a shows a reducing SDS-PAGE (Coomassie-stained) of fractions from .
- Column run in Figure 10 shows a non-reducing.
- SDS- PAGE (Coomassie-stained) of fractions from column run in Figure 10, as indicated. Peak 1 clearly contains TCR heterodimer which is inter-chain disulphide linked.
- Figure 12 is a trace obtained from size-exclusion chromatography of pooled fractions from peak 1 in figure 10. The protein elutes as a single major peak, corresponding to the heterodimer. Yield is 80%;
- Figure 13 - A BIAcore response curve of the specific binding of disulphide-linked JM22 soluble TCR to HLA-Flu complex.
- B Binding response compared to control for a single injection of disulphide-linked JM22 soluble TCR;
- Figures 14a and 14b show the DNA sequence of ⁇ and ⁇ chain of the NY-ESO mutated to include additional cysteine. residues to form a non-native disulphide bond;
- Figures 15a and 15b show respectively the NY-ESO TCR ⁇ and ⁇ chain extracellular amino acid sequences produced from the DNA sequences of Figures 14a and 14b
- FIG 17 - A Reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 16, as indicated.
- B Non-reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 16, as indicated. Peak 1 and 2 clearly contain TCR heterodimer which is inter-chain disulphide linked;
- Figures 20a and 20b show respectively the DNA sequences of the ⁇ and ⁇ chains of a soluble NY-ESO TCR, mutated so as to introduce a novel cysteine codon (indicated by shading).
- the sequences include the cysteine involved in the native disulphide inter-chain bond (indicated by the codon in bold);
- Figure 22 shows a trace obtained from anion exchange chromatography of soluble NY-ESO TCR ⁇ ° ys F ys showing protein elution from a POROS 50HQ column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- Figure 23 shows a trace obtained from anion exchange chromatography of soluble NY-ESO TCRc 5 showing protein elution from a POROS 50HQ column using a 0- 500 mM NaCl gradient, as indicated by the dotted line;
- Figure 24 shows a trace obtained from anion exchange chromatography of soluble NY-ESO TCR/ 1 ' 5 showing protein elution from a POROS 50HQ column using a 0- 500 mM NaCl gradient, as indicated by the dotted line;
- Figure 25 shows a reducing SDS-PAGE (Coomassie-stained) of NY-ESO TCRo ys ⁇ ° ys , TCR ⁇ ° ys , and fractions from anion exchange column runs in Figures 22- 24 respectively.
- Figure 29 is a trace obtained from size exclusion exchange chromatography of soluble NY-ESO TCR ° ys showing protein elution of pooled fractions from Figure 22.
- the protein elutes as a single major peak, corresponding to the heterodimer;
- Figure 31 is a BIAcore response curve of the specific binding of NY-ESO TCRoP ⁇ to HLA-NY-ESO complex
- Figures 33a and 33b show respectively the DNA sequences of the a and ⁇ chains of a soluble AH-1.23 TCR, mutated so as to introduce a novel cysteine codon (indicated by shading).
- the sequences include the cysteine involved in the native disulphide interchain bond (indicated by the codon in bold);
- Figures 34a and 34b show respectively the AH- 1.23 TCR ⁇ and ⁇ chain extracellular amino acid sequences produced from the DNA sequences of Figures 33a and 33b;
- Figures 44a and 44b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 15 in exon 1 of TRAC*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine;
- Figures 47a ⁇ and 47b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 52 in exon 1 of TRAC*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteme;
- Figures 48a and 48b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 43 in exon 1 of TRAC*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine;
- Figures 49a and 49b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 57 in exon 1 of TRAC*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteme;
- Figures 50a and 50b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 77 in exon 1 of TRBC2*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine;
- Figures 54a and 54b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 79 in exon 1 of TRBC2*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine;
- Figures 55a and 55b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 14 in exon 1 of TRBC2*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine;
- Figures 57a and 57b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 63 in exon 1 of TRBC2*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine
- Figures 58a and 58b show respectively the DNA and amino acid sequences of the ⁇ chain of a soluble A6 TCR, mutated so as to introduce a novel cysteine at residue 15 in exon 1 of TRBC2*01.
- the shaded nucleotides indicate the introduced novel cysteine codon and the underlined amino acid indicates the introduced cysteine;
- Figures 59-64 are traces obtained from anion exchange chromatography of soluble A6 TCR containing a novel disulphide inter-chain bond between: residues 48 of exon 1 of TRAC*01 and 57 of exon 1 of TRBC2*01; residues 45 of exon 1 of TRAC*01 and 77 of exon 1 of TRBC2*01; residues 10 of exon 1 of TRAC*01 and 17 of exon 1 of TRBC2*01; residues 45 of exon 1 of TRAC*01 and 59 of exon 1 of TRBC2*01; residues 52 of exon 1 of TRAC*01 and 55 of exon 1 of TRBC2*01; residues 15 of exon 1 of TRAC*01 and 15 of exon 1 of TRBC2*01, respectively, showing protein elution from a POROS 50 column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- Figures 66a and 66b are, respectively, reducing and non-reducing SDS-PAGE (Coomassie-stained) of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 45 of exon 1 of TRAC*01 and 77 of exon 1. of TRBC2*01, fractions run were collected from anion exchange column run in Figure 60;
- Figures 67a and 67b are, respectively, reducing and non-reducing SDS-PAGE (Coomassie-stained) of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 10 of exon 1 of TRAC*01 and 17 exon 1 of TRBC2*01, fractions run were collected from anion exchange column run in Figure 61;
- Figures 68a and 68b are, respectively, reducing and non-reducing SDS-PAGE (Coomassie-stained) of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 45 of exon 1 of TRAC*01 and 59 of exon 1 of TRBC2*01, fractions run were collected from anion exchange column run in Figure 62;
- Figures 69a and 69b are, respectively, reducing and non-reducing SDS-PAGE (Coomassie-stained) of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 52 of exon 1 of TRAC*01 and 55 of exon 1 of TRBC2*01, fractions run were collected from anion exchange column run in Figure 63;
- Figures 70a and 70b are, respectively, reducing and non-reducing SDS-PAGE (Coomassie-stained) of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 15 of exon 1 of TRAC*01 and 15 of exon 1 of TRBC2*01, fractions run were collected from anion exchange column run in Figure 64;
- Figure 72 is a trace obtained from size exclusion chromatography of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 45 of exon 1 of TRAC*01 and 77 of exon 1 of TRBC2*01, showing protein elution from a Superdex 200 HL gel filtration column. Fractions run were collected from anion exchange column run in Figure 60;
- Figures 77-80 are BIAcore response curves showing, respectively, binding of soluble A6 TCR containing a novel disulphide inter-chain bond between: residues 48 of exon 1 of TRAC*01 and 57 of exon 1 of TRBC2*01; residues 45 of exon 1 of TRAC*01 and 77 of exon 1 of TRBC2*01; residues 10 of exon 1 of TRAC*01 and 17 of exon 1 of TRBC2*01; and residues 45 of exon 1 of TRAC*01 and 59 of exon 1 of TRBC2*01 to HLA-A2-tax pMHC.
- Figure 81 is a BIAcore trace showing non-specific binding of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 52 of exon 1 of TRAC*01 and 55 of exon 1 of TRBC2*01 to HLA-A2-tax and to HLA-A2-NY-ESO pMHC;
- Figure 82 is a BIAcore response curve showing binding of soluble A6 TCR containing a novel disulphide inter-chain bond between residues 15 of exon 1 ofTRAC*01 and 15 of exon 1 of TRBC2*01 to HLA-A2-tax pMHC;
- Figures 85a and 85b show the DNA and amino acid sequences respectively of the ⁇ chain of the NY-ESO TCR incorporating a biotin recognition site. The biotin recognition site is highlighted;
- Figure 87 illustrates the elution of soluble NY-ESO TCR containing a novel disulphide bond and a biotin recognition sequence from a POROS 50HQ anion exchange column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- Figure 93 is an anion exchange chromatography trace of soluble A6 TCR incorporating the TRBC1*01 constant region showing protein elution from a POROS 50HQ column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- Figure 94 - A Reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 93, as indicated.
- B Non-reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 93, as indicated.;
- Figure 99 - A Reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 98, as indicated.
- B Non-reducing SDS-PAGE (Coomassie-stained) of fractions from column run in Figure 98, as indicated;
- Peak 1 contains TCR heterodimer which is inter-chain disulphide linked;
- Figure 102 shows the nucleic acid sequence of the mutated beta chain of the A6 TCR incorporating a serine residue mutated in for the 'free' cysteine;
- FIG 103 Anion exchange chromatography of soluble A6 TCR incorporating a serine residue mutated in for the 'free' cysteine showing protein elution from a POROS 50HQ column using a 0-500 mM NaCl gradient, as indicated by the dotted line;
- Figure 107 shows the nucleotide sequence of pYXl 12
- Figure 114 shows the nucleic acid sequence of disulphide A6 ⁇ TCR construct as a BamHI insert for insertion into pAcAB3 expression plasmid;
- Plasmid DNA was purified on a Qiagen mini-prep column according to the manufacturer's instructions and the sequence was verified by automated sequencing at the sequencing facility of Department of Biochemistry, Oxford University.
- the respective mutated nucleic acid and amino acid sequences are shown in Figures 2a and 3a for the ⁇ chain and Figures 2b and 3b for the ⁇ chain.
- Triton buffer 50mM Tris-HCI, 0.5% Triton-Xl 00, 200mM NaCI, 1 OmM NaEDTA, 0.1% (w/v) NaAzide, 2mM DTT, pH 8.0
- Detergent and salt was then removed by a similar wash in the following buffer: 50mM Tris-HCI, lmM NaEDTA, 0.1% (w/v) NaAzide, 2mM DTT, pH 8.0.
- the inclusion bodies were divided into 30 g aliquots and frozen at -70°C.
- sTCR was separated from degradation products and impurities by loading the dialysed refold onto a POROS 50HQ anion exchange column and eluting bound protein with a gradient of 0-500mM NaCI over 50 column volumes using an Akta purifier (Pharmacia) as in Figure 4. Peak fractions were stored at 4°C and analysed by Coomassie-stained SDS-PAGE ( Figure 5) before being pooled and concentrated. Finally, the sTCR was purified and characterised using a Superdex 200HR gel filtration column ( Figure 6) pre-equilibrated in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.5 mM EDTA, 0.05% nonidet p40). The peak eluting at a relative molecular weight of approximately 50 kDa was pooled and concentrated prior to characterisation by BIAcore surface plasmon resonance analysis.
- TCR Specific binding of TCR is obtained even at low concentrations (at least 40 ⁇ g/ml), implying the TCR is relatively stable.
- the pMHC binding properties of sTCR are observed to be qualitatively and quantitatively similar if sTCR is used either in the soluble or immobilised phase. This is an important control for partial activity of soluble species and also suggests that biotinylated pMHC complexes are biologically as active as non- biotinylated complexes.
- Biotinylated class I HLA-A2 - peptide complexes were refolded in vitro from bacterially-expressed inclusion bodies containing the constituent subunit proteins and synthetic peptide, followed by purification and in vitro enzymatic biotinylation (O'Callaghan et al. (1999) Anal. Biochem. 266: 9-15).
- HLA-heavy chain was expressed with a C-terminal biotinylation tag which replaces the transmembrane and cytoplasmic domains of the protein in an appropriate construct.
- Inclusion body expression levels of -75 mg/litre bacterial culture were obtained.
- the HLA light- chain or ⁇ 2-microglobulin was also expressed as inclusion bodies in E.coli from an appropriate construct, at a level of -500 mg/litre bacterial culture.
- Buffer was exchanged by dialysis in 10 volumes of 10 mM Tris pH 8.1. Two changes of buffer were necessary to reduce the ionic strength of the solution sufficiently.
- the protein solution was then filtered through a 1.5 ⁇ m cellulose acetate filter and loaded onto a POROS 50HQ anion exchange column (8 ml bed volume). Protein was eluted with a linear 0-500 mM NaCl gradient. HLA-A2-peptide complex eluted at approximately 250 mM NaCl, and peak fractions were collected, a cocktail of protease inhibitors (Calbiochem) was added and the fractions were chilled on ice.
- the Kd value obtained (1.8 ⁇ M) is close to that reported for the interaction between A6 Tax sTCR without the novel di-sulphide bond and pMHC (0.91 ⁇ M - Ding et al, 1999, Inmmunity 11:45-56).
- Example 4 Production of soluble JM22 TCR containing a novel disulphide bond.
- the ⁇ chain of the soluble A6 TCR prepared in Example 1 contains in the native sequence a Bglll restriction site (AAGCTT) suitable for use as a ligation site.
- AAGCTT Bglll restriction site
- PCR mutagenesis was carried as detailed below to introduce a BamHI restriction site (GGATCC) into the ⁇ chain of soluble A6 TCR, 5' of the novel cysteine codon.
- GGATCC BamHI restriction site
- the sequence described in Figure 2a was used as a template for this mutagenesis.
- the following primers were used:
- A6 TCR plasmids containing the ⁇ chain BamHI and ⁇ chain Bglll restriction sites were used as templates.
- the following primers were used:
- JM22 TCR ⁇ and ⁇ -chain constructs were obtained by PCR cloning as follows. PCR reactions were performed using the primers as shown above, and templates containing the LM22 TCR chains. The PCR products were restriction digested with the relevant restriction enzymes, and cloned into pGMT7 to obtain expression plasmids. The sequence of the plasmid inserts were confirmed by automated DNA sequencing.
- Figures 8b and 8c show the DNA sequence of the mutated c and ⁇ chains of the JM22 TCR respectively, and Figures 9a and 9b show the resulting amino acid sequences.
- FIG. 10 illustrates the elution of soluble disulphide-linked JM22 TCR protein elution from a POROS 50HQ column using a 0-500 mM NaCl gradient, as indicated by the dotted line.
- Figure 11 shows the results of both reducing SDS- PAGE (Coomassie-stained) and non-reducing SDS-PAGE (Coomassie-stained) gels of fractions from the column run illustrated by Figure 10. Peak 1 clearly contains TCR heterodimer which is inter-chain disulphide linked.
- Figure 12 shows protein elution from a size-exclusion column of pooled fractions from peak 1 in Figure 10.
- FIG. 13a shows BIAcore analysis of the specific binding of disulphide-linked JM22 soluble TCR to HLA-Flu complex.
- Figure 13b shows the binding response compared to control for a single injection of disulphide-linked JM22 soluble TCR.
- the Kd of this disulphide-linked TCR for the HLA-flu complex was determined to be 7.9 ⁇ 0.5 l ⁇ M
- cDNA encoding NY-ESO TCR was isolated from T cells supplied by Enzo Cerundolo (Institute of Molecular Medicine, University of Oxford) according to known techniques. cDNA encoding NY-ESO TCR was produced by treatment of the mRNA with reverse transcriptase.
- NY-ESO TCR ⁇ and ⁇ -chain constructs were obtained by PCR cloning as follows. PCR reactions were performed using the primers as shown above, and templates containing the NY-ESO TCR chains. The PCR products were restriction digested with the relevant restriction enzymes, and cloned into pGMT7 to obtain expression plasmids. The sequence of the plasmid inserts were confirmed by automated DNA sequencing.
- Figures 14a and 14b show the DNA sequence of the mutated and ⁇ chains of the NY-ESO TCR respectively, and Figures 15a and 15b show the resulting amino acid sequences.
- TCR chains were expressed, co-refolded and purified as described in Examples 1 and 2, except for the following alterations in protocol:
- Denaturation of soluble TCRs 30mg of the solubilised TCR /3-chain inclusion body and 60mg of the solubilised TCR ct-chain inclusion body was thawed from frozen stocks.
- the inclusion bodies were diluted to a final concentration of 5mg/ml in 6M guanidine solution, and DTT (2M stock) was added to a final concentration of lOmM.
- the mixture was incubated at 37°C for 30 min.
- Refolding of soluble TCRs 1 L refolding buffer was stirred vigorously at 5°C ⁇ 3°C.
- FIGS. 22-24 illustrate the elution of soluble NY-ESO TCRcf ys /3° ys (i.e. with non- native and native cysteines in both chains), TCR ⁇ ? ys (with non-native cysteines in both chains but the native cysteine in the chain only), and TCR/3° ys (with non-native cysteines in both chains but the native cysteine in the ⁇ chain only) protein elution from POROS 50HQ anion exchange columns using a 0-500 mM NaCl gradient, as indicated by the dotted line.
- Figures 25 and 26 respectively show the results of reducing SDS-PAGE (Coomassie-stained) and non-reducing SDS-PAGE (Coomassie- stained) gels of fractions from the NY-ESO TCRo ys 0**, TCRo , and TCR/3° ys column runs illustrated by Figures 22-24. These clearly indicate that TCR heterodimers which are inter-chain disulphide linked have been formed.
- Figures 27- 29 are protein elution profiles from gel filtration chromatography of pooled fractions from the NY-ESO TCRo ys 1 8 cys , TCRo ys , and TCR/3° ys anion exchange column runs illustrated by Figures 22-24 respectively. The protein elutes as a single major peak, corresponding to the TCR heterodimer.
- TCR ⁇ ⁇ ° ys had a K d of 18.08 ⁇ 2.075 ⁇ M
- TCRo had a K d of 19.24 ⁇ 2.01 ⁇ M
- K d of 22.5 ⁇ 4.0692 ⁇ M.
- cDNA encoding AH-1.23 TCR was isolated from T cells supplied by Hill Gaston (Medical School, Addenbrooke's Hospital, Cambridge) according to known techniques.
- cDNA encoding NY-ESO TCR was produced by treatment of the mRNA with reverse transcriptase. fri order to produce a soluble AH- 1.23 TCR incorporating a novel disulphide bond, TCR plasmids containing the ⁇ chain BamHI and ⁇ chain Bgi ⁇ restriction sites were used as a framework as described in Example 4. The following primers were used:
- TCR chains were expressed, co-refolded and purified as described in Example 5.
- Figure 35 illustrates the elution of soluble AH- 1.23 disulphide-linked TCR protein elution from a POROS 50HQ anion exchange column using a 0-500 mM NaCl gradient, as indicated by the dotted line.
- Figures 36 and 37 show the results of reducing SDS-PAGE (Coomassie-stained) and non-reducing SDS-PAGE (Coomassie- stained) gels respectively of fractions from the column run illustrated by Figure 35. These gels clearly indicate the presence of a TCR heterodimer which is inter-chain disulphide linked.
- Figure 38 is the elution profile from a Superdex 75 HR gel filtration column of pooled fractions from the anion exchange column run illustrated in Figure 35. The protein elutes as a single major peak, corresponding to the heterodimer.
- PCR mutagenesis, a and ⁇ TCR construct amplification, ligation and plasmid purification was carried out as described in Example 1 using the appropriate combination of the above primers in order to produce soluble TCRs including novel disulphide inter-chain bonds between the following pairs of amino acids:
- the refolded NY-ESO TCR was separated from degradation products and impurities by loading the dialysed refold onto a POROS 50HQ (Applied Biosystems) anion exchange column using an AKTA purifier (Amersham Biotech).
- a POROS 50 HQ column was pre-equilibrated with 10 column volumes of buffer A (10 mM Tris pH 8.1) prior to loading with protein.
- the bound protein was eluted with a gradient of 0- 500mM NaCI over 7 column volumes. Peak fractions (1 ml) were analysed on denaturing SDS-PAGE using reducing and non-reducing sample buffer.
- Peak fractions containing the heterodimeric alpha-beta complex were further purified using a Superdex 75HR gel filtration column pre-equilibrated in 25 mM MES pH 6.5.
- the protein peak eluting at a relative molecular weight of approximately 50 kDa was pooled, concentrated to 42 mg/ml in Ultrafree centrifugal concentrators (Millipore, part number UFV2BGC40) and stored at -80 °C.
- the cell dimensions and symmetry meant there were two copies in the cell.
- the asymmetric unit, au or the minimum volume that needs to be studied, has only 1 molecule, and the other molecule in the cell is generated by the 2 ⁇ symmetry operation.
- the positioning of the molecule in the au is arbitrary in the y-direction. As long as it is in the correct position in the x-z plane, it can be translated at will in the y-direction. This is referred to as a free parameter, in this 'polar' space group.
- the PDB data base has only one entry containing an A/B heterodimeric TCR, 1BD2. This entry also has co-ordinates of the HLA-cognate peptide in complex with the TCR.
- the TCR chain B was the same in NY-ESO, but chain A had small differences in the C-domain and significant differences in the N-domain.
- MR molecular replacement
- MR did not have significant clashes with neighbours.
- the correlation coefficient was 49%, the crystallographic R-factor 50%, and the nearest approach (centre-of-gravity to c-o-g) was 0.49 nm (49 A).
- the rotation and translation operation needed to transform the starting chain B model to the MR equivalent, was applied to chain A.
- the hybrid MR solution thus generated, packed well in the cell, with minimal clashes.
- the most important aspect of this work is that the new TCR is very similar in structure to the published model (1BD2).
- the comparison could include all of the TCR, the constant domains, or the small part near the mutation point.
- the short stretch refers to the single strand from Chain A (A157 to A169) and the single strand from Chain B (B170 to B183) that are now joined by the disulphide bridge.
- the deviations were calculated for only the main chain atoms.
- A6 TCR plasmids containing the ⁇ chain BamHI and ⁇ chain Bglll restriction sites were used as frameworks as described in Example 4.
- NY-ESO TCR ⁇ -chain constructs were obtained by PCR cloning as follows. PCR reactions were performed using the primers as shown below, and templates containing the NY-ESO TCR chains.
- Figure 85a shows the DNA sequence of the ⁇ chain of the NY-ESO TCR incorporating the biotin recognition site
- Figure 85b shows the resulting amino acid sequence.
- the ⁇ chain construct was produced as described in Example 5.
- the respective TCR chains were expressed, co-refolded and purified as described in Example 5.
- the NY-ESO soluble TCRs containing a novel disulphide bond and a biotin recognition sequence prepared as in Example 10 were utilised to form the soluble TCR tetramers using required for cell staining.
- 2.5 ml of purified soluble TCR solution ( ⁇ 0.2 mg/ml) was buffer exchanged into biotinylation reaction buffer (50 mM Tris pH 8.0, 10 mM MgCl 2 ) using a PD- ⁇ 0 column (Pharmacia).
- the eluate (3.5 ml) was concentrated to 1 ml using a centricon concentrator (Amicon) with a 10 kDa molecular weight cut-off.
- the level of biotinylation present on the NY-ESO TCR was determined via a size exclusion HPLC-based method as follows. A 50ul aliquot of the biotinylated NYESO TCR (2mg/ml) was incubated with 50ul of streptavidin coated agarose beads (Sigma) for 1 hour. The beads were then spun down, and 50 ⁇ l of the unbound sample was run on a TSK 2000 SW column (Tosoohaas) using a 0.5ml/min flowrate (200mM Phosphate Buffer pH 7.0) over 30 minutes. The presence of the biotinylated NY-ESO TCR was detected by a UV spectrometer at both 214nm and 280nm.
- the biotinylated NY-ESO was run against a non-bioninylated NY-ESO TCR control.
- the percentage of biotinylation was calculated by subtracting the peak-area of the biotinylated protein from that of the non-biotinylated protein.
- Tetramerisation of the biotinylated soluble TCR was achieved using neutravidin- phycoerythrin conjugate (Cambridge Biosciences, UK).
- concentration of biotinylated soluble TCR was measured using a Coomassie protein assay (Pierce), and a ratio of soluble TCR 0.8 mg/mg neutravidin-phycoerthrin conjugate was calculated to achieve saturation of the neutravidin-PE by biotinylated TCR at a ratio of 1 :4.
- HLA-A2 positive EBV transformed B cell line PP LCL
- PBS PBS
- varying concentrations 0, 10 "4 , 10 "5 and 10 "6 M
- HLA-A2 NYESO peptide SLLMWITQC
- Figures 91 a-h illustrate as histograms the FACS Vantage data generated for each of the samples prepared as described above. The following table lists the percentage of positively stained cells observed for each of the samples:
- Example 12 Production of soluble A6 TCR with a novel disulphide bond incorporating the C ⁇ l constant region.
- Beta VTCR construct and C ⁇ l construct were separately amplified using standard PCR technology. They were connected to each other using a stitching PCR. Plasmid DNA was purified on a Qiagen mini-prep column according to the manufacturer's instructions and the sequence was verified by automated sequencing at the sequencing facility of Department of Biochemistry, Oxford University. The sequence for A6+C ⁇ l is shown in Figure 92.
- the soluble TCR was expressed and refolded as described in Example 2.
- sTCR Purification of refolded soluble TCR: sTCR was separated from degradation products and impurities by loading the dialysed refold onto a POROS 50HQ anion exchange column and eluting bound protein with a gradient of 0-500mM NaCI over 50 column volumes using an Akta purifier (Pharmacia) as in Figure 93. Peak fractions were stored at 4°C and analysed by Coomassie-stained SDS-PAGE ( Figure 94) before being pooled and concentrated.
- the sTCR was purified and characterised using a Superdex 200HR gel filtration column (Figure 95) pre-equilibrated in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.5 mM EDTA, 0.05% nonidet ⁇ 40). The peak eluting at a relative molecular weight of approximately 50 kDa was pooled and concentrated prior to characterisation by BIAcore surface plasmon resonance analysis.
- FIG. 96 shows BIAcore analysis of the specific binding of disulphide-linked A6 soluble TCR to its cognate pMHC.
- the soluble A6 TCR with a novel disulphide bond incorporating the C ⁇ l constant region had a K of 2.42 + 0.55 ⁇ M for its cognate pMHC. This value is very similar to the K d of 1.8 ⁇ M determined for the soluble A6 TCR with a novel disulphide bond incorporating the C ⁇ 2 constant region as determined in Example 3.
- the ⁇ chain constant regions of TCRs include a cysteine residue (residue 75 in exon 1 of TRBC1*01 and TRBC2*01) which is not involved in either inter-chain or infra- chain disulphide bond formation. All of the previous examples describe the production of soluble TCRs with a novel disulphide bond in which this "free" cysteine has been mutated to alanine in order to avoid the possible formation of any
- sTCR Purification of refolded soluble TCR: sTCR was separated from degradation products and impurities by loading the dialysed refold onto a POROS 50HQ anion exchange column and eluting bound protein with a gradient of 0-500mM NaCI over 50 column volumes using an Akta purifier
- FIG. 1 A BIAcore analysis of the binding of the disulphide-linked A6 TCR to pMHC was carried out as described in Example 3.
- Figure 101 shows BIAcore analysis of the specific binding of disulphide-linked A6 soluble TCR to its cognate pMHC.
- the soluble A6 TCR with a novel disulphide bond incorporating the "free" cysteine in the ⁇ chain had a Kd of 21.39 ⁇ 3.55 ⁇ M for its cognate pMHC.
- Example 14 Production of soluble A6 TCR with a novel disulphide bond wherein "free " cysteine in the ⁇ chain is mutated to serine .
- the present example demonstrates that soluble TCRs with a novel disulphide bond in which the "free" cysteine in the ⁇ chain (residue 75 in exon 1 of TRBC1*01 and TRBC2*01) is mutated to serine can be successfully produced.
- sTCR Purification of refolded soluble TCR: sTCR was separated from degradation products and impurities by loading the dialysed refold onto a POROS 50HQ anion exchange column and eluting bound protein with a gradient of 0-500mM NaCI over 50 column volumes using an Akta purifier (Pharmacia) as shown in Figure 103. Peak fractions were stored at 4°C and analysed by Coomassie-stained SDS-PAGE ( Figure 104) before being pooled and concentrated.
- the sTCR was purified and characterised using a Superdex 200HR gel filtration column (Figure 105) pre-equilibrated in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.5 mM EDTA, 0.05% nonidet p40). The peak eluting at a relative molecular weight of approximately 50 kDa was pooled and concentrated prior to characterisation by BIAcore surface plasmon resonance analysis.
- a BIAcore analysis of the binding of the disulphide-linked A6 TCR to pMHC was carried out as described in Example 3.
- Figure 106 shows BIAcore analysis of the specific binding of disulphide-linked A6 soluble TCR to its cognate pMHC.
- the soluble A6 TCR with a novel disulphide bond in which the "free" cysteine in the ⁇ chain was mutated to serine had a K d of 2.98 ⁇ 0.27 ⁇ M for its cognate pMHC. This value is very similar to the K d of 1.8 ⁇ M determined for the soluble A6 TCR with a novel disulphide bond in which the "free" cysteine in the ⁇ chain was mutated to alanine as determined in Example 3.
- NY-ESO TCR ⁇ and ⁇ chains were fused to the C-terminus of the pre-pro mating factor alpha sequence from Saccharomyces cerevisiae and cloned into yeast expression vectors pYX122 and pYXl 12 respectively (see Figures 107 and 108).
- primers were designed to PCR amplify pre-pro mating factor alpha sequence from S. cerevisiae strain SEY6210 (Robinson et al. (1991), Mol Cell Biol. ll(12):5813-24) for fusing to the TCR ⁇ chain.
- the following primers were designed to PCR amplify pre-pro mating factor alpha sequence from S. cerevisiae strain SEY6210 for fusing to the TCR ⁇ chain.
- Yeast DNA was prepared by re-suspending a colony of S. cerevisiae strain SEY6210 in 30 ⁇ l of 0.25% SDS in water and heating for 3 minutes at 90°C.
- the pre-pro mating factor alpha sequences for fusing to the TCR ⁇ and ⁇ chains were generated by PCR amplifing 0.25 ⁇ l of yeast DNA with the respective primer pairs mentioned above using the following PCR conditions. 12.5pmoles of each primer was mixed with 200 ⁇ M dNTP, 5 ⁇ l of lOx Pfu buffer and 1.25units of Pfu polymerase (Stratagene) in a final volume of 50 ⁇ l.
- the reaction mixture was subjected to 30 rounds of denaturation (92°C, 30 se ), annealing (46.9°C, 60 sec), and elongation (72°C, 2 min.) in a Hybaid PCR express PCR machine.
- the following primers were designed to PCR amplify the TCR ⁇ chain to be fused to the pre-pro mating factor alpha sequence mentioned above.
- the following primers were designed to PCR amplify the TCR ⁇ chain to be fused to the pre-pro mating factor alpha sequence mentioned above.
- the PCR conditions for amplifying the TCR ⁇ and ⁇ chains were the same as mentioned above except for the following changes: the DNA template used for amplifying the TCR ⁇ and ⁇ chains were the NY-ESO TCR ⁇ and ⁇ chains respectively (as prepared in Example 5); and the annealing temperature used was 60.1°C.
- PCR products were then used in a PCR stitching reaction utilising the complementary overlapping sequences introduced into the initial PCR products to create a full length chimeric gene.
- the resulting PCR products were digested with the restriction enzymes EcoR I and Xho I and cloned into either pYX122 or pYXl 12 digested with the same enzymes.
- the resulting plasmids were purified on a QiagenTM mini-prep column according to the manufacturer's instructions, and the sequences verified by automated sequencing at the sequencing facility of Genetics Ltd, Queensway, New Milton, Hampshire, United Kingdom.
- Figures 109 and 110 show the DNA and protein sequences of the cloned chimeric products.
- the yeast expression plasmids containing the TCR ⁇ and ⁇ chains respectively produced as described in Example 15 were co-transformed into S. cerevisiae strain SEY6210 using the protocol by Agatep et al. (1998) (Technical Tips Online (http://tto.trends.com) 1:51:P01525).
- a single colony growing on synthetic dropout (SD) agar containing Histidine and Uracil (Qbiogene, Illkirch, France) was cultured overnight at 30°C in 10ml SD media containing Histidine and Uracil. The overnight culture was sub-cultured 1:10 in 10ml of the fresh SD media containing Histidine and Uracil and grown for 4 hours at 30°C.
- SD synthetic dropout
- the culture was centrifuged for 5 minutes at 3800rpm in a Heraeus Megafuge 2.0R (Kendro Laboratory Products Ltd, Bishop's Stortford, Hertfordshire, UK) and the supernatant harvested.
- 5 ⁇ l StratClean Resin (Stratagene) was mixed with the supematent and kept rotating in a blood wheel at 4°C overnight.
- the StrataClean resin was spun down at 38 OOrpm in a Heraeus Megafuge 2. OR and the media discarded.
- the ⁇ and ⁇ chains of the disulphide A6 Tax TCR were cloned from pGMT7 into a pBlueScript KS2- based vector called the pEX172.
- This vector was designed for cloning different MHC class II ⁇ -chains, for insect cell expression, using the leader sequence from DRB1*0101, an Agel site for insertion of different peptide-coding sequences, a linker region, and then Mlul and Sail sites to clone the DR ⁇ chains in front of the Jun Leucine zipper sequence.
- the sequence where pEX 172 differs from pBlueScript II KS-, located between the Kpnl and EcoRI sites of pBlueScript II KS-, is shown in Figure 112.
- this pEX172 was cut with Agel and Sail to remove the linker region and Mlul site, and the TCR chains go in where the peptide sequence would start.
- the TCR sequences were cloned from pGMT7 with a BspEI site at the 5' end (this had Agel compatible sticky ends) and a Sail site at the 3' end.
- the first three residues of the DR ⁇ chain were preserved.
- the BamHI fragment were cut out and subcloned into the pAcAB3 vector, which has homology recombination sites for Baculovirus.
- the pAcAB3 vector has two divergent promoters, one with a BamHI site and one with a Bglll cloning site. There is a Bglll site in the A6 TCR ⁇ -chain, so the A6 TCR ⁇ -chain was inserted into the Bglll site, and the ⁇ -chain was then subcloned into the BamHI site.
- Expression plasmids containing the genes for the disulphide A6 Tax TCR ⁇ or ⁇ chain were used as templates in the following PCR reactions. 1 OOng of ⁇ plasmid was mixed with l ⁇ l lOmM dNTP, 5 ⁇ l lOxPfu-buffer (Stratagene), 1.25 units Pfu polymerase (Stratagene), 50pmol of the A6 ⁇ primers above, and the final volume was adjusted to 50 ⁇ l with H 2 O. A similar reaction mixture was set up for the ⁇ chain, using the ⁇ plasmid and the pair of ⁇ primers.
- the reaction mixtures were subjected to 35 rounds of denaturation (95°C, 60 sec), annealing (50°C, 60 sec), and elongation (72°C, 8 min.) in a Hybaid PCR express PCR machine.
- the product was then digested for 2 hours at 37°C with 10 units of BspEI restriction enzyme then for a further 2 hours with 10 units of Sail (New England Biolabs).
- BspEI restriction enzyme then for a further 2 hours with 10 units of Sail (New England Biolabs).
- These digested reactions were ligated into pEX172 that had been digested with Agel and Sail, and these were transformed into competent XL1 -Blue bacteria and grown for 18 hours at 37°C.
- ⁇ and ⁇ disulphide A6 Tax TCR chain constructs in pEX172 were digested out for 2 hours at 37°C with BamHI restriction enzyme (New England Biolabs).
- the ⁇ chain BamHI insert was ligated into pAcAB3 vector (Pharmingen-BD Biosciences: 21216P) that had been digested with Bglll enzyme. This was transformed into competent XLl-Blue bacteria and grown for 18 hours at 37°C. A single colony was picked from this plate and grown overnight in 5 ml TYP + ampicillin and the plasmid DNA was purified as before.
- This plasmid was then digested with BamHI and the ⁇ chain BamHI insert was ligated in, transformed into competent XLl-Blue bacteria, grown overnight, picked to TYP-ampicillin, and grown before miniprepping as before using a QIAgen mini-prep column.
- the correct orientation of both the ⁇ and ⁇ chains were confirmed by sequencing using the following sequencing primers:
- the expression plasmid containing the ⁇ -chain and ⁇ -chain was transfected into sf9 cells (Pharmingen-BD Biosciences: 21300C) grown in serum free medium (Pharmingen-BD Biosciences: 551411), using the Baculogold transfection kit (Pharmingen-BD Biosciences: 21100K) as per the manufacturers instructions. After 5 days at 27°C, 200 ⁇ l of the medium these transfected cells had been growing in was added to 100ml of High Five cells at lxlO 6 cells/ml in serum free medium. After a further 6 days at 27°C, 1ml of this medium was removed and centrifuged at 13,000RPM in a Hereus microfuge for 5 minutes to pellet cell debris.
- the gel was rufi at 150 volts for 1 hour in a No vex - Xcell gel tank after which the gel was stained in 50ml of Coomassie gel stain for 1 hour with gentle agitation (l.lg Coomassie powder in 500ml of methanol stir for 1 hour add 100ml acetic acid make up to 1 litre with H 2 O and stir for 1 hour then filter through 0.45 ⁇ M filter).
- the gel was de-stained three times for 30 mins with gentle agitation in 50ml of de-stain (as Coomassie gel stain but omitting the Coomassie powder).
- the membrane was blocked in 7.5mls of blocking buffer (4 Tris- buffered saline tablets (Sigma: T5030), 3g non-fat dried milk (Sigma: M7409), 30 ⁇ l of Tween 20 made up to 3 Omls with H 2 O) for 60 mins with gentle agitation.
- the membrane was washed three times for 5 mins with TBS wash buffer (20 TBS tablets, 150 ⁇ l Tween 20 made up to 300ml with H 2 O).
- the membrane was then incubated in primary antibody 1 in 50 dilution of anti TCR ⁇ chain clone 3A8 (Serotec: MCA987) or anti TCR ⁇ chain clone 8A3 (Serotec: MCA988) in 7.5ml blocking buffer for 1 hour with gentle agitation.
- the membrane was washed as before in TBS wash buffer.
- a secondary antibody incubation of HRP labelled goat anti-mouse antibody (Santa Cruz Biotech: Sc-2005) 1 in 1000 dilution in 7.5ml of blocking buffer was carried out for 30 min with gentle agitation.
- the membrane was washed as before and then washed in 30ml of H 2 O with 2 TBS tablets.
- the antibody binding was detected by Opti-4CN colourmetric detection (Biorad: 170- 8235) (1.4ml Opt-4CN diluent, 12.6ml H 2 0, 0.28ml Opti-4CN substrate).
- Opti-4CN colourmetric detection Biorad: 170- 8235
- the membranes were coloured for 30 minutes and then washed in H 2 O for 15 minutes.
- the membranes were dried at room temperature, and scanned images were aligned with an image of the coomassie stained gel ( Figure 116).
- both disulphide TCRs are formed as a heterodimer that is stable in the SDS gel. They both break into the ⁇ and ⁇ chains upon reduction.
- the insect disulphide TCR heterodimer has a slightly higher molecular weight that the bacterially produced version, presumably because of the glycosylation from the insect cells. It can be seen that in this instance the insect cells are producing ⁇ chain in excess, and free ⁇ chain can be seen in the non-reduced lane of the anti- ⁇ western blot.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003525033A JP4317940B2 (en) | 2001-08-31 | 2002-08-30 | material |
AT02755287T ATE290020T1 (en) | 2001-08-31 | 2002-08-30 | SOLUBLE T CELL RECEPTOR |
MXPA04001974A MXPA04001974A (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor. |
DE60203125T DE60203125T2 (en) | 2001-08-31 | 2002-08-30 | SOLUBLE T CELL RECEPTOR |
EP02755287A EP1421115B1 (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor |
NZ531208A NZ531208A (en) | 2001-08-31 | 2002-08-30 | Multivalent soluble T cell receptor (TCR) complexes |
EA200400384A EA006601B1 (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor |
DK02755287T DK1421115T3 (en) | 2001-08-31 | 2002-08-30 | Soluble T cell receptor |
KR1020047003158A KR100945977B1 (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor |
IL16035902A IL160359A0 (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor |
AU2002321581A AU2002321581C1 (en) | 2001-08-31 | 2002-08-30 | Soluble T cell receptor |
US10/486,924 US7329731B2 (en) | 2001-08-31 | 2002-08-30 | Soluble T cell receptor |
CA2457652A CA2457652C (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor |
CN028192796A CN1561343B (en) | 2001-08-31 | 2002-08-30 | Soluble T cell receptor |
IL160359A IL160359A (en) | 2001-08-31 | 2004-02-12 | Soluble t cell receptor |
NO20041325A NO331877B1 (en) | 2001-08-31 | 2004-03-30 | Soluble α-form T cell receptor (sTCR), multivalent T cell receptor (TCR) complex, nucleic acid molecule, vector, host cell and method for providing all or part of the T cell receptor, process for proving MHC peptide complexes, and pharmaceutical formulation containing sTCR or multivalent TCR complex. |
HK04109015A HK1066018A1 (en) | 2001-08-31 | 2004-11-15 | Soluble t cell receptor. |
US11/926,391 US7763718B2 (en) | 2001-08-31 | 2007-10-29 | Soluble T cell receptors |
US11/926,480 US20080125369A1 (en) | 2001-08-31 | 2007-10-29 | Soluble t cell receptors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0121187A GB0121187D0 (en) | 2001-08-31 | 2001-08-31 | Substances |
GB0121187.9 | 2001-08-31 | ||
US40418202P | 2002-08-16 | 2002-08-16 | |
GB0219146A GB0219146D0 (en) | 2002-08-16 | 2002-08-16 | Substances |
US60/404,182 | 2002-08-16 | ||
GB0219146.8 | 2002-08-16 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10486924 A-371-Of-International | 2002-08-30 | ||
US11/926,480 Continuation US20080125369A1 (en) | 2001-08-31 | 2007-10-29 | Soluble t cell receptors |
US11/926,391 Division US7763718B2 (en) | 2001-08-31 | 2007-10-29 | Soluble T cell receptors |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003020763A2 true WO2003020763A2 (en) | 2003-03-13 |
WO2003020763A3 WO2003020763A3 (en) | 2003-05-22 |
WO2003020763A9 WO2003020763A9 (en) | 2004-04-22 |
Family
ID=27256272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/003986 WO2003020763A2 (en) | 2001-08-31 | 2002-08-30 | Soluble t cell receptor |
Country Status (17)
Country | Link |
---|---|
US (3) | US7329731B2 (en) |
EP (1) | EP1421115B1 (en) |
JP (1) | JP4317940B2 (en) |
CN (1) | CN1561343B (en) |
AT (1) | ATE290020T1 (en) |
AU (1) | AU2002321581C1 (en) |
CA (1) | CA2457652C (en) |
DE (1) | DE60203125T2 (en) |
ES (1) | ES2239246T3 (en) |
HK (1) | HK1066018A1 (en) |
IL (2) | IL160359A0 (en) |
MX (1) | MXPA04001974A (en) |
NO (1) | NO331877B1 (en) |
NZ (1) | NZ531208A (en) |
PL (1) | PL208712B1 (en) |
PT (1) | PT1421115E (en) |
WO (1) | WO2003020763A2 (en) |
Cited By (266)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004044004A2 (en) * | 2002-11-09 | 2004-05-27 | Avidex Limited | T cell receptor display |
WO2004074322A1 (en) * | 2003-02-22 | 2004-09-02 | Avidex Ltd | Modified soluble t cell receptor |
WO2005113595A2 (en) * | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
WO2005116646A1 (en) * | 2004-05-26 | 2005-12-08 | Avidex Ltd | Method for the identification of a polypeptide which binds to a given pmhc complex |
WO2005116075A1 (en) * | 2004-05-26 | 2005-12-08 | Avidex Ltd. | High affinity telomerase t cell receptors |
WO2005116074A2 (en) * | 2004-05-26 | 2005-12-08 | Avidex Ltd | Nucleoproteins displaying native t cell receptor libraries |
WO2006000830A2 (en) * | 2004-06-29 | 2006-01-05 | Avidex Ltd | Cells expressing a modified t cell receptor |
WO2006037960A2 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd. | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
WO2006054096A2 (en) * | 2004-11-18 | 2006-05-26 | Avidex Ltd | Soluble bifunctional proteins |
WO2006056733A1 (en) * | 2004-11-23 | 2006-06-01 | Avidex Ltd | Gamma-delta t cell receptors |
WO2006103429A2 (en) * | 2005-04-01 | 2006-10-05 | Medigene Limited | High affinity hiv t cell receptors |
WO2006129085A2 (en) | 2005-06-01 | 2006-12-07 | Medigene Limited | High affinity melan-a t cell receptors |
WO2010133828A1 (en) * | 2009-05-20 | 2010-11-25 | Immunocore Ltd. | Bifunctional polypeptides |
WO2011001152A1 (en) | 2009-07-03 | 2011-01-06 | Immunocore Ltd | T cell receptors |
US8017730B2 (en) * | 2005-05-25 | 2011-09-13 | Immunocore Limited | T cell receptors which specifically bind to VYGFVRACL-HLA-A24 |
EP2330120A3 (en) * | 2004-06-02 | 2011-11-16 | AdAlta Pty Ltd | Binding moieties based on Shark IgNAR domains |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
WO2013041865A1 (en) | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
WO2014096803A1 (en) | 2012-12-21 | 2014-06-26 | Immunocore Limited | Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
US8785601B2 (en) | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
WO2016073794A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
WO2017044661A1 (en) | 2015-09-09 | 2017-03-16 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
WO2017046202A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046201A1 (en) | 2015-09-15 | 2017-03-23 | Adaptimmune Limited | Tcr libraries |
WO2017046205A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046211A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046212A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046207A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017053905A1 (en) | 2015-09-24 | 2017-03-30 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
WO2017053902A1 (en) | 2015-09-25 | 2017-03-30 | Abvitro Llc | High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
WO2017089759A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from prorelaxin h1 (rln1) |
WO2017089761A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from actin-like protein 8 (actl8) |
WO2017089773A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089774A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089771A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides from piwil1 |
WO2017089777A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from lengsin (lgsn), complexes comprising such peptides bound to mhc molecules |
WO2017089758A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides of page5 |
WO2017089764A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from transient receptor potential cation channel subfamily m member 1 (trpm1), complexes comprising such peptides bound to mhc molecules |
WO2017089779A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from achaete-scute homolog 2 (ascl2), complexes comprising such peptides bound to mhc molecules |
WO2017089776A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089787A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from alpha-fetoprotein (afp), complexes comprising such peptides bound to mhc molecules |
WO2017089763A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089772A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from kallikrein 4 |
WO2017089768A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089781A2 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089769A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089788A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089765A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089778A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from homeobox protein b13 (hox-b13) and complexes comprising such peptides bound to mhc molecules |
WO2017089762A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089782A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089760A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from p antigen family member 2 (page2) |
WO2017089775A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089784A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from sarcoma antigen 1 (sage1 ) and complexes comprising such peptides bound to mhc molecules |
WO2017089770A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089783A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089780A2 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089756A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc molecules |
WO2017089766A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides from npsr1 |
WO2017122098A2 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
US9732141B2 (en) | 2003-12-06 | 2017-08-15 | Imperial Innovations Limited | Therapeutically useful molecules |
WO2017158367A1 (en) | 2016-03-16 | 2017-09-21 | Immunocore Limited | Peptides |
WO2017163064A1 (en) | 2016-03-23 | 2017-09-28 | Immunocore Limited | T cell receptors |
WO2017174822A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
WO2017174824A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
WO2017187186A1 (en) | 2016-04-29 | 2017-11-02 | Immunocore Limited | Claudin-6 peptides |
WO2017187185A1 (en) | 2016-04-29 | 2017-11-02 | Immunocore Limited | Peptides of bromodomain testis-specific protein (brdt) |
WO2017208018A1 (en) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
WO2018005556A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018057051A1 (en) | 2016-09-24 | 2018-03-29 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
EP3216801A4 (en) * | 2014-11-07 | 2018-04-11 | Guangdong Xiangxue Life Sciences, Ltd. | Soluble heterodimeric t cell receptor, and preparation method and use thereof |
WO2018067618A1 (en) | 2016-10-03 | 2018-04-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
WO2018083505A1 (en) | 2016-11-07 | 2018-05-11 | Immunocore Limited | Peptides |
WO2018085731A2 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
WO2018093591A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
WO2018102785A2 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
WO2018102786A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
WO2018102787A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
WO2018132739A2 (en) | 2017-01-13 | 2018-07-19 | Agenus Inc. | T cell receptors that bind to ny-eso-1 and methods of use thereof |
WO2018132518A1 (en) | 2017-01-10 | 2018-07-19 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
WO2018134691A2 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
WO2018140427A1 (en) | 2017-01-25 | 2018-08-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
WO2018148180A2 (en) | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
WO2018148671A1 (en) | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
WO2018157171A2 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
WO2018170188A2 (en) | 2017-03-14 | 2018-09-20 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
WO2018187791A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
WO2018191723A1 (en) | 2017-04-14 | 2018-10-18 | Juno Therapeutics, Inc. | Methods for assessing cell surface glycosylation |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
WO2018195019A1 (en) | 2017-04-18 | 2018-10-25 | The Broad Institute Inc. | Compositions for detecting secretion and methods of use |
US10112994B2 (en) | 2014-11-05 | 2018-10-30 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2018204427A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
WO2018218222A1 (en) | 2017-05-26 | 2018-11-29 | Goldfless Stephen Jacob | High-throughput polynucleotide library sequencing and transcriptome analysis |
WO2018223098A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019027850A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
WO2019032929A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
WO2019032927A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
WO2019046856A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
WO2019046832A1 (en) | 2017-09-01 | 2019-03-07 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2019090364A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
WO2019090004A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
WO2019109053A1 (en) | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
WO2019113556A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
WO2019113559A2 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
US10344074B2 (en) | 2013-07-26 | 2019-07-09 | Adaptimmune Limited | T cell receptors |
WO2019152743A1 (en) | 2018-01-31 | 2019-08-08 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
WO2019162043A1 (en) | 2018-02-26 | 2019-08-29 | Medigene Immunotherapies Gmbh | Nyeso tcr |
WO2019195486A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
WO2019195491A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
WO2019195492A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
WO2019219709A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
EP3590958A1 (en) | 2014-03-14 | 2020-01-08 | Immunocore Limited | Tcr libraries |
WO2020030631A1 (en) | 2018-08-06 | 2020-02-13 | Medigene Immunotherapies Gmbh | Ha-1 specific t cell receptors and their use |
WO2020033916A1 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for assessing integrated nucleic acids |
WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
WO2020053304A2 (en) | 2018-09-14 | 2020-03-19 | Scancell Limited | Epitopes |
WO2020056047A1 (en) | 2018-09-11 | 2020-03-19 | Juno Therapeutics, Inc. | Methods for mass spectrometry analysis of engineered cell compositions |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
EP3650548A1 (en) | 2013-12-20 | 2020-05-13 | Oxford BioMedica (UK) Limited | Viral vector production system |
WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
WO2020097132A1 (en) | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
WO2020113188A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2020148372A1 (en) | 2019-01-17 | 2020-07-23 | Immunocore Limited | Formulations |
WO2020157211A1 (en) | 2019-01-30 | 2020-08-06 | Immunocore Limited | Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide |
WO2020157210A1 (en) | 2019-01-30 | 2020-08-06 | Immunocore Limited | Cd3-specific binding molecules |
US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191365A1 (en) | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
EP3534916A4 (en) * | 2016-10-11 | 2020-09-30 | Bluebird Bio, Inc. | TCRa HOMING ENDONUCLEASE VARIANTS |
WO2020193745A1 (en) | 2019-03-28 | 2020-10-01 | Immunocore Limited | Binding molecules specfic for hbv envelope protein |
WO2020201318A1 (en) | 2019-04-04 | 2020-10-08 | Medigene Immunotherapies Gmbh | Magea1 specific t cell receptors and their use |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
WO2020230142A1 (en) | 2019-05-15 | 2020-11-19 | Neotx Therapeutics Ltd. | Cancer treatment |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2020247832A1 (en) | 2019-06-07 | 2020-12-10 | Juno Therapeutics, Inc. | Automated t cell culture |
WO2020252218A1 (en) | 2019-06-12 | 2020-12-17 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
WO2021005108A1 (en) | 2019-07-09 | 2021-01-14 | Medigene Immunotherapies Gmbh | Magea10 specific t cell receptors and their use |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021046072A1 (en) | 2019-09-06 | 2021-03-11 | Eli Lilly And Company | Proteins comprising t-cell receptor constant domains |
US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2021078774A1 (en) | 2019-10-22 | 2021-04-29 | Immunocore Limited | Specific binding molecules |
WO2021084050A1 (en) | 2019-10-30 | 2021-05-06 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
WO2021113770A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
WO2021154887A1 (en) | 2020-01-28 | 2021-08-05 | Juno Therapeutics, Inc. | Methods for t cell transduction |
US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
US11124556B2 (en) | 2015-09-15 | 2021-09-21 | Immunocore Limited | TCR libraries |
WO2021214022A1 (en) | 2020-04-21 | 2021-10-28 | Scancell Limited | Citrullinated nucleophosmin peptides as cancer vaccines |
WO2021224261A1 (en) | 2020-05-05 | 2021-11-11 | Immunocore Limited | Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer |
WO2021231657A1 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
US11183272B2 (en) | 2018-12-21 | 2021-11-23 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
EP3925972A1 (en) | 2016-04-08 | 2021-12-22 | Adaptimmune Ltd | T cell receptors |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
WO2022008418A1 (en) | 2020-07-06 | 2022-01-13 | Immunocore Limited | Specific binding molecules |
WO2022060904A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells |
WO2022063965A1 (en) | 2020-09-24 | 2022-03-31 | Medigene Immunotherapies Gmbh | Mage-a3 specific t cell receptors and their use |
WO2022074464A2 (en) | 2020-03-05 | 2022-04-14 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
WO2022106696A2 (en) | 2020-11-23 | 2022-05-27 | Scancell Limited | Anti-tumour responses to cytokeratins |
WO2022111451A1 (en) | 2020-11-24 | 2022-06-02 | 上海吉倍生物技术有限公司 | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
WO2022118030A1 (en) | 2020-12-02 | 2022-06-09 | Oxford University Innovation Limited | T cell receptors and uses thereof |
US11365254B2 (en) | 2017-09-22 | 2022-06-21 | WuXi Biologics Ireland Limited | Bispecific CD3/CD19 polypeptide complexes |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
EP4023668A1 (en) | 2016-04-08 | 2022-07-06 | Immunocore Limited | T cell receptors |
WO2022171032A1 (en) | 2021-02-10 | 2022-08-18 | 上海吉倍生物技术有限公司 | Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant |
US11427624B2 (en) | 2017-06-20 | 2022-08-30 | Immunocore Limited | T cell receptors |
WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
WO2022187280A1 (en) | 2021-03-01 | 2022-09-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
WO2022204070A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11559589B2 (en) | 2006-05-31 | 2023-01-24 | The Children's Hospital Of Philadelphia | Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy |
US11639374B2 (en) | 2015-12-22 | 2023-05-02 | Immunocore Limited | T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex |
US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
WO2023099622A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment |
WO2023099606A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment of mage-a4 positive cancer |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
WO2023156663A1 (en) | 2022-02-20 | 2023-08-24 | Immunocore Limited | Hiv-specific binding molecules and tcr |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2023183344A1 (en) | 2022-03-21 | 2023-09-28 | Alaunos Therapeutics, Inc. | Methods for identifying neoantigen-reactive t cell receptors |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
US11845803B2 (en) | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
US11845796B2 (en) | 2017-09-22 | 2023-12-19 | WuXi Biologics Ireland Limited | Bispecific polypeptide complexes |
WO2024006960A1 (en) | 2022-06-29 | 2024-01-04 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
WO2024130179A1 (en) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
WO2024146936A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
WO2024161021A1 (en) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Methods for non-viral manufacturing of engineered immune cells |
WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
WO2024197072A2 (en) | 2023-03-21 | 2024-09-26 | Alaunos Therapeutics, Inc. | Identification of neoantigen-reactive t cell receptors |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
US20060116824A1 (en) * | 2004-12-01 | 2006-06-01 | Ishikawa Muriel Y | System and method for modulating a humoral immune response |
US20060122783A1 (en) * | 2004-08-24 | 2006-06-08 | Ishikawa Muriel Y | System and method for heightening a humoral immune response |
US20060047435A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to augmenting an immune system |
US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
US20060095211A1 (en) * | 2003-12-05 | 2006-05-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for modulating a cell mediated immune response |
US20060047436A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for magnifying an immune response |
US20060047434A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to improving an immune system |
US20060182742A1 (en) * | 2004-08-24 | 2006-08-17 | Ishikawa Muriel Y | System and method for magnifying a humoral immune response |
US20060047433A1 (en) * | 2004-08-24 | 2006-03-02 | Ishikawa Muriel Y | System and method related to enhancing an immune system |
US20060047437A1 (en) * | 2004-08-25 | 2006-03-02 | Ishikawa Muriel Y | System and method for heightening an immune response |
US20070265818A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for heightening cell-mediated immune response |
US20060047439A1 (en) * | 2004-08-24 | 2006-03-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for improving a humoral immune response |
US20070265819A1 (en) * | 2004-08-24 | 2007-11-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems for improving cell-mediated immune response |
US20070198196A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods relating to ameliorating an immune system |
US20070196362A1 (en) * | 2004-08-24 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to bolster an immune response |
US20070207492A1 (en) * | 2004-08-24 | 2007-09-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems to adjust a humoral immune response |
EA018897B1 (en) | 2005-01-05 | 2013-11-29 | Ф-Стар Биотехнологише Форшунгс- Унд Энтвиклунгсгез.М.Б.Х. | Molecules of immunoglobulin comprising modification in a structural loop regions with binding properties and method for manufacturing same |
US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
AT503861B1 (en) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING T-CELL RECEPTORS |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
JP2011530506A (en) * | 2008-08-07 | 2011-12-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | A truncated analog of a glucose-dependent insulinotropic polypeptide |
ES2781754T3 (en) | 2008-11-07 | 2020-09-07 | Adaptive Biotechnologies Corp | Methods for monitoring conditions by sequence analysis |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
DK2387627T3 (en) | 2009-01-15 | 2016-07-04 | Adaptive Biotechnologies Corp | Adaptive immunity profiling and methods for producing monoclonal antibodies |
KR20120044941A (en) | 2009-06-25 | 2012-05-08 | 프레드 헛친슨 켄서 리서치 센터 | Method of measuring adaptive immunity |
CN102295702B (en) * | 2011-08-26 | 2014-01-29 | 中国科学院微生物研究所 | Preparation method of specific single-chain antibody aimed at T cell receptor variable range |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
EP2768982A4 (en) | 2011-10-21 | 2015-06-03 | Adaptive Biotechnologies Corp | Quantification of adaptive immune cell genomes in a complex mixture of cells |
CN114891797A (en) | 2011-10-28 | 2022-08-12 | 瑞泽恩制药公司 | T cell receptor gene modified mice |
EP3388535B1 (en) | 2011-12-09 | 2021-03-24 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
EP2823060B1 (en) | 2012-03-05 | 2018-02-14 | Adaptive Biotechnologies Corporation | Determining paired immune receptor chains from frequency matched subunits |
AU2013259544B9 (en) | 2012-05-08 | 2017-09-28 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
ES2835200T3 (en) | 2012-05-22 | 2021-06-22 | Us Health | Medical use of cells comprising anti-NY-ESO-1 T cell receptors |
AU2013295652B2 (en) | 2012-07-27 | 2018-02-08 | The Board Of Trustees Of The University Of Illinois | Engineering T-cell receptors |
US20160002731A1 (en) | 2012-10-01 | 2016-01-07 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
TW202423993A (en) | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | Recombinant cell surface capture proteins |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
PT3071593T (en) * | 2013-11-22 | 2019-06-27 | The Board Of Trustees Of The Univ Of Illionis | Engineered high-affinity human t cell receptors |
WO2015134787A2 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
ES2777529T3 (en) | 2014-04-17 | 2020-08-05 | Adaptive Biotechnologies Corp | Quantification of adaptive immune cell genomes in a complex mixture of cells |
EP3172325B1 (en) | 2014-07-22 | 2023-06-28 | The University of Notre Dame du Lac | Molecular constructs and uses thereof |
US9711252B1 (en) | 2014-10-28 | 2017-07-18 | Michelle Corning | High energy beam diffraction material treatment system |
US10629318B1 (en) | 2014-10-28 | 2020-04-21 | Michelle Corning | Neutron beam diffraction material treatment system |
US9938026B1 (en) | 2014-10-28 | 2018-04-10 | Michelle Corning | Energy beam propulsion system |
CA2966201A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
EP3498866A1 (en) | 2014-11-25 | 2019-06-19 | Adaptive Biotechnologies Corp. | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
CN105985427A (en) * | 2015-02-06 | 2016-10-05 | 广州市香雪制药股份有限公司 | High-affinity NY-ESO T cell receptor |
AU2016222788B2 (en) | 2015-02-24 | 2022-03-31 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
EP4248744A3 (en) * | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
CN106279404A (en) * | 2015-05-20 | 2017-01-04 | 广州市香雪制药股份有限公司 | A kind of solvable and stable heterogeneous dimerization TCR |
US20170119820A1 (en) | 2015-07-31 | 2017-05-04 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
CN109312402A (en) * | 2016-04-11 | 2019-02-05 | 得克萨斯州大学系统董事会 | For detecting the method and composition of single T cell receptor affinity and sequence |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
CN110520530A (en) | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | Tumor infiltrating lymphocyte and treatment method |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
JPWO2019151392A1 (en) * | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | Antigen-specific MHC expression regulation method |
CN110818802B (en) * | 2018-08-08 | 2022-02-08 | 华夏英泰(北京)生物技术有限公司 | Chimeric T cell receptor STAR and application thereof |
CN113573729A (en) | 2019-01-10 | 2021-10-29 | 詹森生物科技公司 | Prostate novel antigen and uses thereof |
WO2020156405A1 (en) * | 2019-01-28 | 2020-08-06 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel bispecific cd3/cd20 polypeptide complexes |
AU2020233284A1 (en) | 2019-03-01 | 2021-09-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
AU2020243431A1 (en) | 2019-03-18 | 2021-09-30 | Ludwig Institute For Cancer Research Ltd. | A2/NY-ESO-1 specific T cell receptors and uses thereof |
IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
WO2021190580A1 (en) * | 2020-03-26 | 2021-09-30 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific polypeptide complexes, compositions, and methods of preparation and use |
JP2023515270A (en) | 2020-04-21 | 2023-04-12 | テンパス・ラボズ・インコーポレイテッド | TCR/BCR profiling |
WO2022140759A2 (en) | 2020-12-23 | 2022-06-30 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
EP4281473A1 (en) * | 2021-01-19 | 2023-11-29 | Wuxi Biologics Ireland Limited | Polypeptide complexes with improved stability and expression |
TW202309071A (en) | 2021-05-05 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | Antigen binding proteins specifically binding prame |
WO2023288203A2 (en) | 2021-07-12 | 2023-01-19 | Ludwig Institute For Cancer Research Ltd | T cell receptors specific for tumor-associated antigens and methods of use thereof |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999060119A2 (en) * | 1998-05-19 | 1999-11-25 | Avidex, Ltd. | Multivalent t cell receptor complexes |
US6080840A (en) * | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
WO1996021028A2 (en) | 1995-01-03 | 1996-07-11 | Procept, Inc. | Soluble heterodimeric t cell receptors and their antibodies |
US6008026A (en) * | 1997-07-11 | 1999-12-28 | Genencor International, Inc. | Mutant α-amylase having introduced therein a disulfide bond |
GB9922352D0 (en) | 1999-09-21 | 1999-11-24 | Avidex Ltd | Screening method |
GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
-
2002
- 2002-08-30 PL PL368980A patent/PL208712B1/en unknown
- 2002-08-30 CA CA2457652A patent/CA2457652C/en not_active Expired - Lifetime
- 2002-08-30 EP EP02755287A patent/EP1421115B1/en not_active Expired - Lifetime
- 2002-08-30 MX MXPA04001974A patent/MXPA04001974A/en active IP Right Grant
- 2002-08-30 PT PT02755287T patent/PT1421115E/en unknown
- 2002-08-30 JP JP2003525033A patent/JP4317940B2/en not_active Expired - Lifetime
- 2002-08-30 US US10/486,924 patent/US7329731B2/en not_active Expired - Lifetime
- 2002-08-30 CN CN028192796A patent/CN1561343B/en not_active Expired - Lifetime
- 2002-08-30 NZ NZ531208A patent/NZ531208A/en not_active IP Right Cessation
- 2002-08-30 ES ES02755287T patent/ES2239246T3/en not_active Expired - Lifetime
- 2002-08-30 WO PCT/GB2002/003986 patent/WO2003020763A2/en active IP Right Grant
- 2002-08-30 IL IL16035902A patent/IL160359A0/en unknown
- 2002-08-30 AU AU2002321581A patent/AU2002321581C1/en not_active Expired
- 2002-08-30 DE DE60203125T patent/DE60203125T2/en not_active Expired - Lifetime
- 2002-08-30 AT AT02755287T patent/ATE290020T1/en active
-
2004
- 2004-02-12 IL IL160359A patent/IL160359A/en unknown
- 2004-03-30 NO NO20041325A patent/NO331877B1/en not_active IP Right Cessation
- 2004-11-15 HK HK04109015A patent/HK1066018A1/en not_active IP Right Cessation
-
2007
- 2007-10-29 US US11/926,391 patent/US7763718B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/926,480 patent/US20080125369A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080840A (en) * | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
WO1999060119A2 (en) * | 1998-05-19 | 1999-11-25 | Avidex, Ltd. | Multivalent t cell receptor complexes |
Non-Patent Citations (3)
Title |
---|
GARBOCZI DAVID N ET AL: "Structure of the complex between human T-cell receptor, viral peptide and HLA-A2." NATURE (LONDON), vol. 384, no. 6605, 1996, pages 134-141, XP001097273 ISSN: 0028-0836 * |
GOLDEN A ET AL: "High-level production of a secreted, heterodimeric alphabeta murine T-cell receptor in Escherichia coli" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 206, no. 1-2, 7 August 1997 (1997-08-07), pages 163-169, XP004093129 ISSN: 0022-1759 * |
REITER Y ET AL: "Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure." IMMUNITY. UNITED STATES MAR 1995, vol. 2, no. 3, March 1995 (1995-03), pages 281-287, XP009004075 ISSN: 1074-7613 * |
Cited By (384)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9279122B2 (en) | 2002-11-09 | 2016-03-08 | Adaptimmune Limited | T cell receptor display |
WO2004044004A3 (en) * | 2002-11-09 | 2004-09-30 | Avidex Ltd | T cell receptor display |
US9447410B2 (en) | 2002-11-09 | 2016-09-20 | Adaptimmune Limited | T cell receptor display |
US8741814B2 (en) | 2002-11-09 | 2014-06-03 | Immunocore Limited | T cell receptor display |
WO2004044004A2 (en) * | 2002-11-09 | 2004-05-27 | Avidex Limited | T cell receptor display |
EP2048159A1 (en) | 2002-11-09 | 2009-04-15 | Immunocore Ltd. | T cell receptor display |
WO2004074322A1 (en) * | 2003-02-22 | 2004-09-02 | Avidex Ltd | Modified soluble t cell receptor |
US7666604B2 (en) | 2003-02-22 | 2010-02-23 | Immunocore Limited | Modified soluble T cell receptor |
US10450360B2 (en) | 2003-12-06 | 2019-10-22 | Imperial Innovations Limited | Therapeutically useful molecules |
US9732141B2 (en) | 2003-12-06 | 2017-08-15 | Imperial Innovations Limited | Therapeutically useful molecules |
US9512197B2 (en) | 2004-05-19 | 2016-12-06 | Adaptimmune Limited | High affinity NY-ESO T cell receptors |
US8367804B2 (en) | 2004-05-19 | 2013-02-05 | Immunocore Limited | High affinity NY-ESO T cell receptors |
US8143376B2 (en) | 2004-05-19 | 2012-03-27 | Immunocore Limited | High affinity NY-ESO T cell receptor |
WO2005113595A3 (en) * | 2004-05-19 | 2006-06-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
AU2005245664B2 (en) * | 2004-05-19 | 2012-02-02 | Adaptimmune Limited | High affinity NY-ESO T cell receptor |
US9822163B2 (en) | 2004-05-19 | 2017-11-21 | Adaptimmune Limited | High affinity NY-ESO T cell receptors |
US8008438B2 (en) | 2004-05-19 | 2011-08-30 | Immunocore Limited | High affinity NY-ESO T cell receptors |
US9156903B2 (en) | 2004-05-19 | 2015-10-13 | Adaptimmune Limited | High affinity NY-ESO T cell receptors |
WO2005113595A2 (en) * | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
WO2005116074A2 (en) * | 2004-05-26 | 2005-12-08 | Avidex Ltd | Nucleoproteins displaying native t cell receptor libraries |
WO2005116074A3 (en) * | 2004-05-26 | 2006-01-19 | Avidex Ltd | Nucleoproteins displaying native t cell receptor libraries |
WO2005116075A1 (en) * | 2004-05-26 | 2005-12-08 | Avidex Ltd. | High affinity telomerase t cell receptors |
WO2005116646A1 (en) * | 2004-05-26 | 2005-12-08 | Avidex Ltd | Method for the identification of a polypeptide which binds to a given pmhc complex |
AU2009201692B2 (en) * | 2004-06-02 | 2012-08-30 | Adalta Pty Ltd | Binding moieties based on shark IgNAR domains |
EP2330120A3 (en) * | 2004-06-02 | 2011-11-16 | AdAlta Pty Ltd | Binding moieties based on Shark IgNAR domains |
JP2008504043A (en) * | 2004-06-29 | 2008-02-14 | メディジーン リミテッド | Cells expressing modified T cell receptors |
US9115372B2 (en) | 2004-06-29 | 2015-08-25 | Immunocore Limited | Cells expressing modified T cell receptor |
WO2006000830A2 (en) * | 2004-06-29 | 2006-01-05 | Avidex Ltd | Cells expressing a modified t cell receptor |
WO2006000830A3 (en) * | 2004-06-29 | 2006-07-06 | Avidex Ltd | Cells expressing a modified t cell receptor |
US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
WO2006037960A3 (en) * | 2004-10-01 | 2006-08-03 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
WO2006037960A2 (en) * | 2004-10-01 | 2006-04-13 | Avidex Ltd. | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
WO2006054096A3 (en) * | 2004-11-18 | 2006-08-03 | Avidex Ltd | Soluble bifunctional proteins |
WO2006054096A2 (en) * | 2004-11-18 | 2006-05-26 | Avidex Ltd | Soluble bifunctional proteins |
WO2006056733A1 (en) * | 2004-11-23 | 2006-06-01 | Avidex Ltd | Gamma-delta t cell receptors |
EP2301964A1 (en) | 2005-04-01 | 2011-03-30 | Immunocore Ltd. | High affinity HIV T cell receptors |
CN103059128A (en) * | 2005-04-01 | 2013-04-24 | 英美偌科有限公司 | High affinity HIV t cell receptors |
WO2006103429A2 (en) * | 2005-04-01 | 2006-10-05 | Medigene Limited | High affinity hiv t cell receptors |
US8378074B2 (en) | 2005-04-01 | 2013-02-19 | Immunocore Limited | High affinity HIV T cell receptors |
EP2985291A1 (en) | 2005-04-01 | 2016-02-17 | Immunocore Ltd. | High affinity hiv t cell receptors |
US9255135B2 (en) | 2005-04-01 | 2016-02-09 | Immunocore Limited | High affinity HIV T cell receptors |
CN103059128B (en) * | 2005-04-01 | 2016-01-20 | 英美偌科有限公司 | High affinity HIV φt cell receptor |
EP2275441A1 (en) | 2005-04-01 | 2011-01-19 | Immunocore Ltd. | High affinity HIV T cell receptors |
WO2006103429A3 (en) * | 2005-04-01 | 2007-03-15 | Avidex Ltd | High affinity hiv t cell receptors |
US8017730B2 (en) * | 2005-05-25 | 2011-09-13 | Immunocore Limited | T cell receptors which specifically bind to VYGFVRACL-HLA-A24 |
WO2006129085A2 (en) | 2005-06-01 | 2006-12-07 | Medigene Limited | High affinity melan-a t cell receptors |
US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
US11559589B2 (en) | 2006-05-31 | 2023-01-24 | The Children's Hospital Of Philadelphia | Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy |
US9128080B2 (en) | 2006-09-26 | 2015-09-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
US8785601B2 (en) | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
US9688739B2 (en) | 2009-01-28 | 2017-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
AU2010250951B2 (en) * | 2009-05-20 | 2015-04-30 | Immunocore Limited | Bifunctional polypeptides |
US10517960B2 (en) | 2009-05-20 | 2019-12-31 | Immunocore Limited | Bifunctional polypeptides |
EP3112376B1 (en) | 2009-05-20 | 2019-01-23 | Immunocore Ltd. | Bifunctional polypeptides |
WO2010133828A1 (en) * | 2009-05-20 | 2010-11-25 | Immunocore Ltd. | Bifunctional polypeptides |
US10130721B2 (en) | 2009-05-20 | 2018-11-20 | Immunocore Limited | Bifunctional polypeptides |
EP3112377A1 (en) | 2009-05-20 | 2017-01-04 | Immunocore Ltd. | Bifunctional polypeptides |
EP3112376A2 (en) | 2009-05-20 | 2017-01-04 | Immunocore Ltd. | Bifunctional polypeptides |
US10576162B2 (en) | 2009-05-20 | 2020-03-03 | Immunocore Limited | Bifunctional polypeptides |
US10420846B2 (en) | 2009-05-20 | 2019-09-24 | Immunocore Limited | Bifunctional polypeptides |
EP3112377B1 (en) | 2009-05-20 | 2018-04-18 | Immunocore Ltd. | Bifunctional polypeptides |
EA020841B1 (en) * | 2009-05-20 | 2015-02-27 | Иммунокор Лтд. | Bifunctional polypeptides |
EP3112376A3 (en) * | 2009-05-20 | 2017-03-29 | Immunocore Ltd. | Bifunctional polypeptides |
AU2010267758C1 (en) * | 2009-07-03 | 2015-01-22 | Immunocore Ltd. | T cell receptors |
EA026918B1 (en) * | 2009-07-03 | 2017-05-31 | Иммунокор Лтд. | T cell receptors |
AU2010267758B2 (en) * | 2009-07-03 | 2014-09-04 | Immunocore Ltd. | T cell receptors |
WO2011001152A1 (en) | 2009-07-03 | 2011-01-06 | Immunocore Ltd | T cell receptors |
US8519100B2 (en) | 2009-07-03 | 2013-08-27 | Immunocore Ltd. | Non-naturally occurring T cell receptors |
US9068178B2 (en) | 2009-07-03 | 2015-06-30 | Immunocore Ltd. | Nucleic acid molecules encoding non-naturally occurring T cell receptors and cells thereof |
WO2013041865A1 (en) | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
EP3373013A1 (en) | 2012-12-21 | 2018-09-12 | Immunocore Limited | Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
EP3373013B1 (en) * | 2012-12-21 | 2023-07-19 | Immunocore Limited | Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
WO2014096803A1 (en) | 2012-12-21 | 2014-06-26 | Immunocore Limited | Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
EP4297036A2 (en) | 2012-12-21 | 2023-12-27 | Immunocore Limited | Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
US11929151B2 (en) | 2012-12-21 | 2024-03-12 | Immunocore Limited | Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
US11017882B2 (en) | 2012-12-21 | 2021-05-25 | Immunocore Limited | Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex |
US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US11084862B2 (en) | 2013-07-26 | 2021-08-10 | Adaptimmune Limited | T cell receptors |
US10344074B2 (en) | 2013-07-26 | 2019-07-09 | Adaptimmune Limited | T cell receptors |
EP3578188A1 (en) | 2013-07-26 | 2019-12-11 | Adaptimmune Limited | T cell receptors |
US11834718B2 (en) | 2013-11-25 | 2023-12-05 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
EP3650548A1 (en) | 2013-12-20 | 2020-05-13 | Oxford BioMedica (UK) Limited | Viral vector production system |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
EP3590958A1 (en) | 2014-03-14 | 2020-01-08 | Immunocore Limited | Tcr libraries |
US11091530B2 (en) | 2014-11-05 | 2021-08-17 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US10066002B2 (en) * | 2014-11-05 | 2018-09-04 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
CN107075548A (en) * | 2014-11-05 | 2017-08-18 | 基因泰克公司 | The method that dichain proteins matter is produced in bacterium |
US20160159880A1 (en) * | 2014-11-05 | 2016-06-09 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US10112994B2 (en) | 2014-11-05 | 2018-10-30 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
EP3753948A1 (en) * | 2014-11-05 | 2020-12-23 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US11299539B2 (en) | 2014-11-05 | 2022-04-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
CN107075548B (en) * | 2014-11-05 | 2021-08-10 | 基因泰克公司 | Method for producing double-stranded proteins in bacteria |
WO2016073794A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
US11851469B2 (en) | 2014-11-07 | 2023-12-26 | Xlifesc, Ltd. | Soluble heterodimeric T cell receptor, and preparation method and use thereof |
EP3216801A4 (en) * | 2014-11-07 | 2018-04-11 | Guangdong Xiangxue Life Sciences, Ltd. | Soluble heterodimeric t cell receptor, and preparation method and use thereof |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
US11939637B2 (en) | 2014-12-19 | 2024-03-26 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
US10835585B2 (en) | 2015-05-20 | 2020-11-17 | The Broad Institute, Inc. | Shared neoantigens |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
WO2017044661A1 (en) | 2015-09-09 | 2017-03-16 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
WO2017046207A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
US11136575B2 (en) | 2015-09-15 | 2021-10-05 | Immunocore Limited | TCR libraries |
US11124556B2 (en) | 2015-09-15 | 2021-09-21 | Immunocore Limited | TCR libraries |
WO2017046212A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046211A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046205A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017046201A1 (en) | 2015-09-15 | 2017-03-23 | Adaptimmune Limited | Tcr libraries |
WO2017046202A1 (en) | 2015-09-15 | 2017-03-23 | Immunocore Limited | Tcr libraries |
WO2017053905A1 (en) | 2015-09-24 | 2017-03-30 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
EP3933047A1 (en) | 2015-09-24 | 2022-01-05 | AbVitro LLC | Affinity-oligonucleotide conjugates and uses thereof |
WO2017053902A1 (en) | 2015-09-25 | 2017-03-30 | Abvitro Llc | High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
US11180730B2 (en) | 2015-10-28 | 2021-11-23 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
US11884717B2 (en) | 2015-11-19 | 2024-01-30 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
WO2017089778A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from homeobox protein b13 (hox-b13) and complexes comprising such peptides bound to mhc molecules |
WO2017089783A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
US10792333B2 (en) | 2015-11-23 | 2020-10-06 | Immunocore Limited | Peptides derived from actin-like protein 8 (ACTL8) |
WO2017089759A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from prorelaxin h1 (rln1) |
WO2017089761A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from actin-like protein 8 (actl8) |
WO2017089773A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089774A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089771A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides from piwil1 |
WO2017089777A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from lengsin (lgsn), complexes comprising such peptides bound to mhc molecules |
WO2017089758A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides of page5 |
WO2017089764A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from transient receptor potential cation channel subfamily m member 1 (trpm1), complexes comprising such peptides bound to mhc molecules |
WO2017089779A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from achaete-scute homolog 2 (ascl2), complexes comprising such peptides bound to mhc molecules |
WO2017089766A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides from npsr1 |
WO2017089756A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from kita-kyushu lung cancer antigen (kklc1, ct83, cxorf61) and complexes comprising such peptides bound to mhc molecules |
WO2017089776A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089780A2 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089787A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from alpha-fetoprotein (afp), complexes comprising such peptides bound to mhc molecules |
WO2017089775A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089763A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089770A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089772A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from kallikrein 4 |
EP3974443A2 (en) | 2015-11-23 | 2022-03-30 | Immunocore Limited | Peptides derived from melanoma-associated antigen b2 (mageb2) |
WO2017089768A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
US10980893B2 (en) | 2015-11-23 | 2021-04-20 | Immunocore Limited | Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules |
WO2017089784A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from sarcoma antigen 1 (sage1 ) and complexes comprising such peptides bound to mhc molecules |
WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089781A2 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089769A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089788A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089765A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089762A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089782A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
WO2017089760A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides derived from p antigen family member 2 (page2) |
US11639374B2 (en) | 2015-12-22 | 2023-05-02 | Immunocore Limited | T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex |
US11607452B2 (en) | 2016-01-10 | 2023-03-21 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
US11202829B2 (en) | 2016-01-10 | 2021-12-21 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
WO2017122098A2 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
US10314910B2 (en) | 2016-01-10 | 2019-06-11 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
WO2017158367A1 (en) | 2016-03-16 | 2017-09-21 | Immunocore Limited | Peptides |
WO2017163064A1 (en) | 2016-03-23 | 2017-09-28 | Immunocore Limited | T cell receptors |
US11505590B2 (en) | 2016-04-08 | 2022-11-22 | Immunocore Limited | T cell receptors |
EP4023668A1 (en) | 2016-04-08 | 2022-07-06 | Immunocore Limited | T cell receptors |
EP3988565A1 (en) | 2016-04-08 | 2022-04-27 | Adaptimmune Limited | T cell receptors |
EP4389898A2 (en) | 2016-04-08 | 2024-06-26 | Adaptimmune Ltd | T cell receptors |
EP3925972A1 (en) | 2016-04-08 | 2021-12-22 | Adaptimmune Ltd | T cell receptors |
WO2017174822A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
WO2017174824A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
WO2017187185A1 (en) | 2016-04-29 | 2017-11-02 | Immunocore Limited | Peptides of bromodomain testis-specific protein (brdt) |
WO2017187186A1 (en) | 2016-04-29 | 2017-11-02 | Immunocore Limited | Claudin-6 peptides |
WO2017208018A1 (en) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
US11827688B2 (en) | 2016-06-02 | 2023-11-28 | Immunocore Limited | Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein |
WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
EP3992632A1 (en) | 2016-06-27 | 2022-05-04 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
WO2018005556A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018057051A1 (en) | 2016-09-24 | 2018-03-29 | Abvitro Llc | Affinity-oligonucleotide conjugates and uses thereof |
WO2018067618A1 (en) | 2016-10-03 | 2018-04-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
EP3534916A4 (en) * | 2016-10-11 | 2020-09-30 | Bluebird Bio, Inc. | TCRa HOMING ENDONUCLEASE VARIANTS |
US11896615B2 (en) | 2016-10-13 | 2024-02-13 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
EP4190335A1 (en) | 2016-10-13 | 2023-06-07 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
WO2018093591A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
WO2018085731A2 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
WO2018083505A1 (en) | 2016-11-07 | 2018-05-11 | Immunocore Limited | Peptides |
US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
EP4279136A2 (en) | 2016-12-03 | 2023-11-22 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
WO2018102785A2 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
WO2018102786A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
WO2018102787A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
WO2018132518A1 (en) | 2017-01-10 | 2018-07-19 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
US11821027B2 (en) | 2017-01-10 | 2023-11-21 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
WO2018132739A2 (en) | 2017-01-13 | 2018-07-19 | Agenus Inc. | T cell receptors that bind to ny-eso-1 and methods of use thereof |
US11517627B2 (en) | 2017-01-20 | 2022-12-06 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
WO2018134691A2 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2018140427A1 (en) | 2017-01-25 | 2018-08-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
WO2018148180A2 (en) | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
US11650211B2 (en) | 2017-02-12 | 2023-05-16 | Biontech Us Inc. | HLA-based methods and compositions and uses thereof |
WO2018148671A1 (en) | 2017-02-12 | 2018-08-16 | Neon Therapeutics, Inc. | Hla-based methods and compositions and uses thereof |
EP4287191A2 (en) | 2017-02-12 | 2023-12-06 | BioNTech US Inc. | Hla-based methods and compositions and uses thereof |
US11845803B2 (en) | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
WO2018157171A2 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
EP4353818A2 (en) | 2017-02-27 | 2024-04-17 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
WO2018170188A2 (en) | 2017-03-14 | 2018-09-20 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
US11963966B2 (en) | 2017-03-31 | 2024-04-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018187791A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
WO2018191723A1 (en) | 2017-04-14 | 2018-10-18 | Juno Therapeutics, Inc. | Methods for assessing cell surface glycosylation |
US11796534B2 (en) | 2017-04-14 | 2023-10-24 | Juno Therapeutics, Inc. | Methods for assessing cell surface glycosylation |
WO2018195019A1 (en) | 2017-04-18 | 2018-10-25 | The Broad Institute Inc. | Compositions for detecting secretion and methods of use |
EP4327878A2 (en) | 2017-05-01 | 2024-02-28 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
WO2018204427A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
US12049667B2 (en) | 2017-05-26 | 2024-07-30 | Abvitro Llc | High-throughput polynucleotide library sequencing and transcriptome analysis |
WO2018218222A1 (en) | 2017-05-26 | 2018-11-29 | Goldfless Stephen Jacob | High-throughput polynucleotide library sequencing and transcriptome analysis |
WO2018223098A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
US11740231B2 (en) | 2017-06-02 | 2023-08-29 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
US11944647B2 (en) | 2017-06-02 | 2024-04-02 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US12018062B2 (en) | 2017-06-20 | 2024-06-25 | Immunocore Limited | T cell receptors |
EP4219541A2 (en) | 2017-06-20 | 2023-08-02 | Immunocore Limited | T cell receptors |
US11427624B2 (en) | 2017-06-20 | 2022-08-30 | Immunocore Limited | T cell receptors |
EP4219542A2 (en) | 2017-06-20 | 2023-08-02 | Immunocore Limited | T cell receptors |
US11718657B2 (en) | 2017-06-20 | 2023-08-08 | Immunocore Limited | T cell receptors |
WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
WO2019027850A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Reagents for expanding cells expressing recombinant receptors |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
EP4026554A1 (en) | 2017-08-03 | 2022-07-13 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US10864259B2 (en) | 2017-08-03 | 2020-12-15 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019027465A1 (en) | 2017-08-03 | 2019-02-07 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
WO2019032927A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
US11851678B2 (en) | 2017-08-09 | 2023-12-26 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
WO2019032929A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
WO2019046832A1 (en) | 2017-09-01 | 2019-03-07 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
WO2019046856A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US11365254B2 (en) | 2017-09-22 | 2022-06-21 | WuXi Biologics Ireland Limited | Bispecific CD3/CD19 polypeptide complexes |
US11845796B2 (en) | 2017-09-22 | 2023-12-19 | WuXi Biologics Ireland Limited | Bispecific polypeptide complexes |
US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
EP4215543A2 (en) | 2017-10-03 | 2023-07-26 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
WO2019090004A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
WO2019090364A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
WO2019109053A1 (en) | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
WO2019113559A2 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
WO2019113556A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
WO2019152743A1 (en) | 2018-01-31 | 2019-08-08 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
WO2019162043A1 (en) | 2018-02-26 | 2019-08-29 | Medigene Immunotherapies Gmbh | Nyeso tcr |
EP4424710A2 (en) | 2018-02-26 | 2024-09-04 | Medigene Immunotherapies GmbH | Nyeso tcr |
WO2019195492A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
WO2019195486A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
US11471489B2 (en) | 2018-04-05 | 2022-10-18 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
WO2019195491A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019219709A1 (en) | 2018-05-14 | 2019-11-21 | Immunocore Limited | Bifunctional binding polypeptides |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2020030631A1 (en) | 2018-08-06 | 2020-02-13 | Medigene Immunotherapies Gmbh | Ha-1 specific t cell receptors and their use |
WO2020033916A1 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for assessing integrated nucleic acids |
WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
WO2020041384A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity |
WO2020041387A1 (en) | 2018-08-20 | 2020-02-27 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
WO2020068304A2 (en) | 2018-08-20 | 2020-04-02 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
WO2020056047A1 (en) | 2018-09-11 | 2020-03-19 | Juno Therapeutics, Inc. | Methods for mass spectrometry analysis of engineered cell compositions |
WO2020053304A2 (en) | 2018-09-14 | 2020-03-19 | Scancell Limited | Epitopes |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
WO2020097132A1 (en) | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
EP4427810A2 (en) | 2018-11-30 | 2024-09-11 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
WO2020113188A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
EP4393547A2 (en) | 2018-11-30 | 2024-07-03 | Juno Therapeutics, Inc. | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
US11183272B2 (en) | 2018-12-21 | 2021-11-23 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
EP4279082A2 (en) | 2019-01-17 | 2023-11-22 | Immunocore Limited | Formulations |
WO2020148372A1 (en) | 2019-01-17 | 2020-07-23 | Immunocore Limited | Formulations |
WO2020157211A1 (en) | 2019-01-30 | 2020-08-06 | Immunocore Limited | Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide |
WO2020157210A1 (en) | 2019-01-30 | 2020-08-06 | Immunocore Limited | Cd3-specific binding molecules |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020191365A1 (en) | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
WO2020193767A1 (en) | 2019-03-27 | 2020-10-01 | Medigene Immunotherapies Gmbh | Mage a4 t cell receptors |
EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
WO2020193745A1 (en) | 2019-03-28 | 2020-10-01 | Immunocore Limited | Binding molecules specfic for hbv envelope protein |
WO2020201318A1 (en) | 2019-04-04 | 2020-10-08 | Medigene Immunotherapies Gmbh | Magea1 specific t cell receptors and their use |
WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
WO2020230142A1 (en) | 2019-05-15 | 2020-11-19 | Neotx Therapeutics Ltd. | Cancer treatment |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2020247832A1 (en) | 2019-06-07 | 2020-12-10 | Juno Therapeutics, Inc. | Automated t cell culture |
WO2020252218A1 (en) | 2019-06-12 | 2020-12-17 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
WO2021005108A1 (en) | 2019-07-09 | 2021-01-14 | Medigene Immunotherapies Gmbh | Magea10 specific t cell receptors and their use |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021046072A1 (en) | 2019-09-06 | 2021-03-11 | Eli Lilly And Company | Proteins comprising t-cell receptor constant domains |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
WO2021078774A1 (en) | 2019-10-22 | 2021-04-29 | Immunocore Limited | Specific binding molecules |
WO2021084050A1 (en) | 2019-10-30 | 2021-05-06 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
WO2021113770A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
WO2021154887A1 (en) | 2020-01-28 | 2021-08-05 | Juno Therapeutics, Inc. | Methods for t cell transduction |
WO2022074464A2 (en) | 2020-03-05 | 2022-04-14 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
WO2021214022A1 (en) | 2020-04-21 | 2021-10-28 | Scancell Limited | Citrullinated nucleophosmin peptides as cancer vaccines |
WO2021224261A1 (en) | 2020-05-05 | 2021-11-11 | Immunocore Limited | Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer |
WO2021231657A1 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
WO2022008418A1 (en) | 2020-07-06 | 2022-01-13 | Immunocore Limited | Specific binding molecules |
WO2022060904A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells |
WO2022063965A1 (en) | 2020-09-24 | 2022-03-31 | Medigene Immunotherapies Gmbh | Mage-a3 specific t cell receptors and their use |
US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
WO2022106696A2 (en) | 2020-11-23 | 2022-05-27 | Scancell Limited | Anti-tumour responses to cytokeratins |
WO2022111451A1 (en) | 2020-11-24 | 2022-06-02 | 上海吉倍生物技术有限公司 | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
WO2022118030A1 (en) | 2020-12-02 | 2022-06-09 | Oxford University Innovation Limited | T cell receptors and uses thereof |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
WO2022171032A1 (en) | 2021-02-10 | 2022-08-18 | 上海吉倍生物技术有限公司 | Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant |
WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
WO2022187280A1 (en) | 2021-03-01 | 2022-09-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
WO2022204070A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
WO2023099622A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment |
WO2023099606A1 (en) | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment of mage-a4 positive cancer |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
WO2023156663A1 (en) | 2022-02-20 | 2023-08-24 | Immunocore Limited | Hiv-specific binding molecules and tcr |
WO2023183344A1 (en) | 2022-03-21 | 2023-09-28 | Alaunos Therapeutics, Inc. | Methods for identifying neoantigen-reactive t cell receptors |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2024006960A1 (en) | 2022-06-29 | 2024-01-04 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
US12065475B2 (en) | 2022-08-18 | 2024-08-20 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
WO2024130179A1 (en) | 2022-12-16 | 2024-06-20 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
WO2024146936A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
WO2024161021A1 (en) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Methods for non-viral manufacturing of engineered immune cells |
WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
WO2024197072A2 (en) | 2023-03-21 | 2024-09-26 | Alaunos Therapeutics, Inc. | Identification of neoantigen-reactive t cell receptors |
Also Published As
Publication number | Publication date |
---|---|
JP2005514006A (en) | 2005-05-19 |
EP1421115B1 (en) | 2005-03-02 |
WO2003020763A3 (en) | 2003-05-22 |
AU2002321581B2 (en) | 2008-02-21 |
DE60203125D1 (en) | 2005-04-07 |
NO331877B1 (en) | 2012-04-23 |
IL160359A0 (en) | 2004-07-25 |
DE60203125T2 (en) | 2006-04-06 |
CA2457652A1 (en) | 2003-03-13 |
WO2003020763A9 (en) | 2004-04-22 |
EP1421115A2 (en) | 2004-05-26 |
CA2457652C (en) | 2012-08-07 |
ES2239246T3 (en) | 2005-09-16 |
US7329731B2 (en) | 2008-02-12 |
US20050009025A1 (en) | 2005-01-13 |
NO20041325L (en) | 2004-03-30 |
PT1421115E (en) | 2005-07-29 |
NZ531208A (en) | 2005-08-26 |
US20080153131A1 (en) | 2008-06-26 |
HK1066018A1 (en) | 2005-03-11 |
ATE290020T1 (en) | 2005-03-15 |
AU2002321581C1 (en) | 2008-09-18 |
MXPA04001974A (en) | 2004-07-16 |
PL208712B1 (en) | 2011-05-31 |
CN1561343B (en) | 2012-06-06 |
US7763718B2 (en) | 2010-07-27 |
JP4317940B2 (en) | 2009-08-19 |
IL160359A (en) | 2010-11-30 |
CN1561343A (en) | 2005-01-05 |
US20080125369A1 (en) | 2008-05-29 |
PL368980A1 (en) | 2005-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1421115B1 (en) | Soluble t cell receptor | |
AU2002321581A1 (en) | Soluble T cell receptor | |
EP1594896B1 (en) | Modified soluble t cell receptor | |
EP1549748B1 (en) | Single chain recombinant t cell receptors | |
EP2275441B1 (en) | High affinity HIV T cell receptors | |
WO2016124142A1 (en) | High affinity ny-eso t cell receptor | |
WO2016184258A1 (en) | Soluble and stable heterodimeric tcr | |
JP2008510678A (en) | High affinity telomerase T cell receptor | |
EP3216801B1 (en) | Soluble heterodimeric t cell receptor, and preparation method and use thereof | |
ZA200401197B (en) | Soluble T cell receptor. | |
KR20040039322A (en) | Substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 160359 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/01197 Country of ref document: ZA Ref document number: 2457652 Country of ref document: CA Ref document number: 200401197 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 531208 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002321581 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001974 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003525033 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047003158 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047003593 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002755287 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 647/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028192796 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200400384 Country of ref document: EA |
|
COP | Corrected version of pamphlet |
Free format text: DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION, PAGES 32/81 AND 36/81, DRAWINGS, REPLACED BY CORRECT PAGES 32/81 AND 36/81 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020047003593 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020047003593 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047003158 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2002755287 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10486924 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002755287 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 531208 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 531208 Country of ref document: NZ |